{
  "model": "chatgpt-gpt-5.3-codex-spark",
  "taskId": "tumor-vaccine-ici",
  "runIndex": 3,
  "result": {
    "text": "âœ… **Completion checklist**\n- [x] `output/study_overview.json` written\n- [x] `output/quantitative_findings.json` written\n- [x] `output/claim_audit.json` written\n- [x] `output/public_summary.json` written",
    "thoughts": "",
    "steps": [
      {
        "step": 1,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "list_directory",
            "input": {
              "dir_path": ".",
              "ignore": [
                ".git",
                "node_modules"
              ],
              "file_filtering_options": {
                "respect_git_ignore": true,
                "respect_gemini_ignore": true
              }
            },
            "output": "input/\noutput/\nschemas/\nTASK.md",
            "callId": "call_S2r2ni9gqyzBGO03tKXtyP4g"
          }
        ],
        "usage": {
          "promptTokens": 571,
          "cachedTokens": 0,
          "responseTokens": 49,
          "thinkingTokens": 69,
          "totalTokens": 689
        },
        "costUsd": 0.00037874999999999996
      },
      {
        "step": 2,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "TASK.md",
              "offset": 0,
              "limit": 300
            },
            "output": "L1: # Agent Task\nL2: \nL3: Task id: tumor-vaccine-ici\nL4: Task title: mRNA tumor sensitization for checkpoint blockade\nL5: Reference paper: SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\nL6: Reference URL: https://www.nature.com/articles/s41586-025-09006-8\nL7: \nL8: ## Objective\nL9: Read the report and produce all required JSON outputs that satisfy their schemas.\nL10: \nL11: ## Inputs On Disk\nL12: - Report: `input/report.md`\nL13: - Schemas: in `schemas/`\nL14: \nL15: ## Required Outputs\nL16: - `output/study_overview.json` (schema: `schemas/study_overview.schema.json`)\nL17: - `output/quantitative_findings.json` (schema: `schemas/quantitative_findings.schema.json`)\nL18: - `output/claim_audit.json` (schema: `schemas/claim_audit.schema.json`)\nL19: - `output/public_summary.json` (schema: `schemas/public_summary.schema.json`)\nL20: \nL21: ## Constraints\nL22: - Do not invent source facts; derive calculations only from values in the report.\nL23: - Use line refs as `L<number>` where required.\nL24: - Where quotes are required, copy exact report snippets.\nL25: - For calculation outputs, line_refs must include every report line used for equations, constants, and numeric substitutions.\nL26: - Use relative paths only.\nL27: - Never use absolute paths.\nL28: - Never use `..` in paths.\nL29: - Write valid JSON only.\nL30: \nL31: ## Completion\nL32: Respond with a checklist of written output files.\nL33: After the checklist, stop. Do not call more tools.",
            "callId": "call_JjUhpDrbv0fHFZSHnDERD86m"
          }
        ],
        "usage": {
          "promptTokens": 637,
          "cachedTokens": 0,
          "responseTokens": 30,
          "thinkingTokens": 56,
          "totalTokens": 723
        },
        "costUsd": 0.00033124999999999995
      },
      {
        "step": 3,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "list_directory",
            "input": {
              "dir_path": "input",
              "ignore": [
                ".git"
              ],
              "file_filtering_options": {
                "respect_git_ignore": true,
                "respect_gemini_ignore": true
              }
            },
            "output": "report.md",
            "callId": "call_9f7A4oD2HuHxjN4eFi9MRj4g"
          },
          {
            "toolName": "list_directory",
            "input": {
              "dir_path": "schemas",
              "ignore": [
                ".git"
              ],
              "file_filtering_options": {
                "respect_git_ignore": true,
                "respect_gemini_ignore": true
              }
            },
            "output": "claim_audit.schema.json\npublic_summary.schema.json\nquantitative_findings.schema.json\nstudy_overview.schema.json",
            "callId": "call_EMq44xMaOAsXedeikguzGQWM"
          }
        ],
        "usage": {
          "promptTokens": 1087,
          "cachedTokens": 0,
          "responseTokens": 103,
          "thinkingTokens": 39,
          "totalTokens": 1229
        },
        "costUsd": 0.0005557499999999999
      },
      {
        "step": 4,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "input/report.md",
              "offset": 0,
              "limit": 800
            },
            "output": "L1: # Structured Paper Report: Tumor Sensitization by mRNA Vaccination\nL2: \nL3: ## Citation\nL4: - Title: SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\nL5: - Journal: Nature\nL6: - Year: 2025\nL7: - DOI: 10.1038/s41586-025-09006-8\nL8: - Source URL: https://www.nature.com/articles/s41586-025-09006-8\nL9: \nL10: ## One-Paragraph Context\nL11: Immune checkpoint inhibitors (ICIs) can produce durable responses in some cancers, but many tumors remain non-responsive due to weak antigen presentation or poor immune priming. The paper investigates whether intratumoral delivery of an mRNA vaccine can create an interferon-rich inflammatory state that improves sensitivity to anti-PD-L1 therapy.\nL12: \nL13: ## Study Design Snapshot\nL14: - Preclinical arm: multiple murine tumor models with intratumoral mRNA vaccine and anti-PD-L1 combinations.\nL15: - Translational arm: a retrospective cohort of metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.\nL16: - Mechanistic probes: immunopeptidomics, transcriptomics, and perturbation controls (including IFNAR1 blockade and non-mRNA particle controls).\nL17: \nL18: ## Cohorts and Scenarios\nL19: 1. Mouse efficacy cohort (combination therapy): 78 tumor-bearing mice pooled across repeat experiments.\nL20: 2. Mouse control cohort (vaccine only, ICI only, and vehicle): 84 tumor-bearing mice pooled across matched controls.\nL21: 3. Human retrospective metastatic cohort: 130 patients total.\nL22: 4. Human vaccinated subgroup: 43 patients.\nL23: 5. Human unvaccinated subgroup: 87 patients.\nL24: \nL25: ## Quantitative Findings\nL26: | Metric | Vaccine/Combination Arm | Comparator | Interpretation |\nL27: |---|---:|---:|---|\nL28: | Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination |\nL29: | Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape |\nL30: | Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment |\nL31: | Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors |\nL32: | PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable |\nL33: | Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x | Increased immune infiltration with combination therapy |\nL34: \nL35: ## Controls and Null/Conditional Results\nL36: - Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\nL37: - ICI-only treatment had limited activity in low-immunogenic baseline settings.\nL38: - Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\nL39: - Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\nL40: \nL41: ## Mechanistic Chain Proposed by Authors\nL42: 1. Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\nL43: 2. Interferon-associated antigen processing and presentation pathways increase.\nL44: 3. A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\nL45: 4. PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.\nL46: 5. Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\nL47: \nL48: ## Caveats and Threats to Validity\nL49: - The human analysis is retrospective and non-randomized; residual confounding is likely.\nL50: - Vaccination timing relative to ICI initiation varied across patients.\nL51: - Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\nL52: - Mouse model effects may not map one-to-one to all human tumors.\nL53: - Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\nL54: \nL55: ## Practical Takeaway\nL56: The study supports a biologically coherent hypothesis that intratumoral mRNA vaccination can prime tumors for stronger ICI responses, but prospective randomized studies are required before clinical protocol changes are justified.",
            "callId": "call_Q0qSqX4SWZnfAUU2S1QsTZ56"
          }
        ],
        "usage": {
          "promptTokens": 1222,
          "cachedTokens": 0,
          "responseTokens": 31,
          "thinkingTokens": 45,
          "totalTokens": 1298
        },
        "costUsd": 0.0004575
      },
      {
        "step": 5,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/study_overview.schema.json",
              "offset": 0,
              "limit": 400
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-study_overview\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"paper\": {\nL7:       \"type\": \"object\",\nL8:       \"properties\": {\nL9:         \"title\": {\nL10:           \"type\": \"string\",\nL11:           \"minLength\": 10\nL12:         },\nL13:         \"doi\": {\nL14:           \"type\": \"string\",\nL15:           \"pattern\": \"^10\\\\.\"\nL16:         },\nL17:         \"publication_year\": {\nL18:           \"type\": \"integer\",\nL19:           \"minimum\": 1900,\nL20:           \"maximum\": 2100\nL21:         },\nL22:         \"domain\": {\nL23:           \"type\": \"string\",\nL24:           \"enum\": [\nL25:             \"oncology-immunology\",\nL26:             \"exoplanet-atmospheres\",\nL27:             \"climate-science\",\nL28:             \"neuroscience\",\nL29:             \"other\"\nL30:           ]\nL31:         },\nL32:         \"study_type\": {\nL33:           \"type\": \"string\",\nL34:           \"enum\": [\nL35:             \"preclinical+retrospective\",\nL36:             \"observational-astronomy\",\nL37:             \"randomized-trial\",\nL38:             \"simulation\",\nL39:             \"mixed\"\nL40:           ]\nL41:         }\nL42:       },\nL43:       \"required\": [\nL44:         \"title\",\nL45:         \"doi\",\nL46:         \"publication_year\",\nL47:         \"domain\",\nL48:         \"study_type\"\nL49:       ],\nL50:       \"additionalProperties\": false\nL51:     },\nL52:     \"core_question\": {\nL53:       \"type\": \"string\",\nL54:       \"minLength\": 20\nL55:     },\nL56:     \"datasets_or_cohorts\": {\nL57:       \"type\": \"array\",\nL58:       \"items\": {\nL59:         \"type\": \"object\",\nL60:         \"properties\": {\nL61:           \"id\": {\nL62:             \"type\": \"string\",\nL63:             \"pattern\": \"^[a-z0-9-]+$\"\nL64:           },\nL65:           \"label\": {\nL66:             \"type\": \"string\",\nL67:             \"minLength\": 3\nL68:           },\nL69:           \"sample_size_or_observations\": {\nL70:             \"type\": \"string\",\nL71:             \"minLength\": 1\nL72:           },\nL73:           \"description\": {\nL74:             \"type\": \"string\",\nL75:             \"minLength\": 20\nL76:           }\nL77:         },\nL78:         \"required\": [\nL79:           \"id\",\nL80:           \"label\",\nL81:           \"sample_size_or_observations\",\nL82:           \"description\"\nL83:         ],\nL84:         \"additionalProperties\": false\nL85:       },\nL86:       \"minItems\": 2,\nL87:       \"maxItems\": 8\nL88:     },\nL89:     \"major_limitations\": {\nL90:       \"type\": \"array\",\nL91:       \"items\": {\nL92:         \"type\": \"string\",\nL93:         \"minLength\": 12\nL94:       },\nL95:       \"minItems\": 3,\nL96:       \"maxItems\": 8\nL97:     }\nL98:   },\nL99:   \"required\": [\nL100:     \"paper\",\nL101:     \"core_question\",\nL102:     \"datasets_or_cohorts\",\nL103:     \"major_limitations\"\nL104:   ],\nL105:   \"additionalProperties\": false\nL106: }",
            "callId": "call_xa6NO3tA6tN7T6Anm30Bk1aK"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/quantitative_findings.schema.json",
              "offset": 0,
              "limit": 800
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-quantitative_findings\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"findings\": {\nL7:       \"type\": \"array\",\nL8:       \"items\": {\nL9:         \"type\": \"object\",\nL10:         \"properties\": {\nL11:           \"id\": {\nL12:             \"type\": \"string\",\nL13:             \"pattern\": \"^Q[0-9]{2}$\"\nL14:           },\nL15:           \"metric\": {\nL16:             \"type\": \"string\",\nL17:             \"minLength\": 6\nL18:           },\nL19:           \"value\": {\nL20:             \"type\": \"string\",\nL21:             \"minLength\": 1\nL22:           },\nL23:           \"comparator_or_baseline\": {\nL24:             \"type\": \"string\",\nL25:             \"minLength\": 1\nL26:           },\nL27:           \"interpretation\": {\nL28:             \"type\": \"string\",\nL29:             \"minLength\": 12\nL30:           },\nL31:           \"evidence_line_refs\": {\nL32:             \"type\": \"array\",\nL33:             \"items\": {\nL34:               \"type\": \"string\",\nL35:               \"pattern\": \"^L[1-9]\\\\d*$\"\nL36:             },\nL37:             \"minItems\": 1,\nL38:             \"maxItems\": 3\nL39:           }\nL40:         },\nL41:         \"required\": [\nL42:           \"id\",\nL43:           \"metric\",\nL44:           \"value\",\nL45:           \"comparator_or_baseline\",\nL46:           \"interpretation\",\nL47:           \"evidence_line_refs\"\nL48:         ],\nL49:         \"additionalProperties\": false\nL50:       },\nL51:       \"minItems\": 5,\nL52:       \"maxItems\": 14\nL53:     },\nL54:     \"controls_or_null_results\": {\nL55:       \"type\": \"array\",\nL56:       \"items\": {\nL57:         \"type\": \"object\",\nL58:         \"properties\": {\nL59:           \"statement\": {\nL60:             \"type\": \"string\",\nL61:             \"minLength\": 10\nL62:           },\nL63:           \"evidence_line_ref\": {\nL64:             \"$ref\": \"#/definitions/schemas-quantitative_findings/properties/findings/items/properties/evidence_line_refs/items\"\nL65:           }\nL66:         },\nL67:         \"required\": [\nL68:           \"statement\",\nL69:           \"evidence_line_ref\"\nL70:         ],\nL71:         \"additionalProperties\": false\nL72:       },\nL73:       \"minItems\": 2,\nL74:       \"maxItems\": 10\nL75:     }\nL76:   },\nL77:   \"required\": [\nL78:     \"findings\",\nL79:     \"controls_or_null_results\"\nL80:   ],\nL81:   \"additionalProperties\": false\nL82: }",
            "callId": "call_gohW2Cc7DVub11Vl84fVbTLp"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/claim_audit.schema.json",
              "offset": 0,
              "limit": 1200
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-claim_audit\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"claims\": {\nL7:       \"type\": \"array\",\nL8:       \"items\": {\nL9:         \"type\": \"object\",\nL10:         \"properties\": {\nL11:           \"claim_id\": {\nL12:             \"type\": \"string\",\nL13:             \"pattern\": \"^C[0-9]{2}$\"\nL14:           },\nL15:           \"claim\": {\nL16:             \"type\": \"string\",\nL17:             \"minLength\": 20\nL18:           },\nL19:           \"strength\": {\nL20:             \"type\": \"string\",\nL21:             \"enum\": [\nL22:               \"strong\",\nL23:               \"moderate\",\nL24:               \"tentative\"\nL25:             ]\nL26:           },\nL27:           \"evidence\": {\nL28:             \"type\": \"array\",\nL29:             \"items\": {\nL30:               \"type\": \"object\",\nL31:               \"properties\": {\nL32:                 \"quote\": {\nL33:                   \"type\": \"string\",\nL34:                   \"minLength\": 10\nL35:                 },\nL36:                 \"line_ref\": {\nL37:                   \"type\": \"string\",\nL38:                   \"pattern\": \"^L[1-9]\\\\d*$\"\nL39:                 }\nL40:               },\nL41:               \"required\": [\nL42:                 \"quote\",\nL43:                 \"line_ref\"\nL44:               ],\nL45:               \"additionalProperties\": false\nL46:             },\nL47:             \"minItems\": 2,\nL48:             \"maxItems\": 3\nL49:           },\nL50:           \"caveat\": {\nL51:             \"type\": \"string\",\nL52:             \"minLength\": 20\nL53:           }\nL54:         },\nL55:         \"required\": [\nL56:           \"claim_id\",\nL57:           \"claim\",\nL58:           \"strength\",\nL59:           \"evidence\",\nL60:           \"caveat\"\nL61:         ],\nL62:         \"additionalProperties\": false\nL63:       },\nL64:       \"minItems\": 4,\nL65:       \"maxItems\": 10\nL66:     }\nL67:   },\nL68:   \"required\": [\nL69:     \"claims\"\nL70:   ],\nL71:   \"additionalProperties\": false\nL72: }",
            "callId": "call_mvT1vdie1M4EAGfd2qaNjkgk"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/public_summary.schema.json",
              "offset": 0,
              "limit": 1200
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-public_summary\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"headline\": {\nL7:       \"type\": \"string\",\nL8:       \"minLength\": 20,\nL9:       \"maxLength\": 120\nL10:     },\nL11:     \"plain_language_summary\": {\nL12:       \"type\": \"string\",\nL13:       \"minLength\": 180,\nL14:       \"maxLength\": 1200\nL15:     },\nL16:     \"what_is_new\": {\nL17:       \"type\": \"array\",\nL18:       \"items\": {\nL19:         \"type\": \"string\",\nL20:         \"minLength\": 20\nL21:       },\nL22:       \"minItems\": 3,\nL23:       \"maxItems\": 3\nL24:     },\nL25:     \"why_caution_is_needed\": {\nL26:       \"type\": \"array\",\nL27:       \"items\": {\nL28:         \"type\": \"string\",\nL29:         \"minLength\": 20\nL30:       },\nL31:       \"minItems\": 3,\nL32:       \"maxItems\": 5\nL33:     },\nL34:     \"glossary\": {\nL35:       \"type\": \"array\",\nL36:       \"items\": {\nL37:         \"type\": \"object\",\nL38:         \"properties\": {\nL39:           \"term\": {\nL40:             \"type\": \"string\",\nL41:             \"minLength\": 2\nL42:           },\nL43:           \"definition\": {\nL44:             \"type\": \"string\",\nL45:             \"minLength\": 20,\nL46:             \"maxLength\": 220\nL47:           }\nL48:         },\nL49:         \"required\": [\nL50:           \"term\",\nL51:           \"definition\"\nL52:         ],\nL53:         \"additionalProperties\": false\nL54:       },\nL55:       \"minItems\": 4,\nL56:       \"maxItems\": 8\nL57:     },\nL58:     \"open_questions\": {\nL59:       \"type\": \"array\",\nL60:       \"items\": {\nL61:         \"type\": \"string\",\nL62:         \"minLength\": 20\nL63:       },\nL64:       \"minItems\": 3,\nL65:       \"maxItems\": 6\nL66:     }\nL67:   },\nL68:   \"required\": [\nL69:     \"headline\",\nL70:     \"plain_language_summary\",\nL71:     \"what_is_new\",\nL72:     \"why_caution_is_needed\",\nL73:     \"glossary\",\nL74:     \"open_questions\"\nL75:   ],\nL76:   \"additionalProperties\": false\nL77: }",
            "callId": "call_FL0uWFAqlTXoLdHlfMIcufek"
          }
        ],
        "usage": {
          "promptTokens": 2326,
          "cachedTokens": 1024,
          "responseTokens": 139,
          "thinkingTokens": 27,
          "totalTokens": 2492
        },
        "costUsd": 0.0006831000000000001
      },
      {
        "step": 6,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/study_overview.json",
              "content": "{\n  \"paper\": {\n    \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\n    \"doi\": \"10.1038/s41586-025-09006-8\",\n    \"publication_year\": 2025,\n    \"domain\": \"oncology-immunology\",\n    \"study_type\": \"preclinical+retrospective\"\n  },\n  \"core_question\": \"Can intratumoral mRNA vaccination sensitize tumors to checkpoint blockade by improving antigen presentation and immune activation?\",\n  \"datasets_or_cohorts\": [\n    {\n      \"id\": \"mouse-efficacy-combination\",\n      \"label\": \"Mouse efficacy cohort\",\n      \"sample_size_or_observations\": \"78 tumor-bearing mice\",\n      \"description\": \"Preclinical arm with intratumoral mRNA vaccine plus anti-PD-L1, pooled across repeat experiments.\"\n    },\n    {\n      \"id\": \"mouse-control-cohort\",\n      \"label\": \"Mouse control arm\",\n      \"sample_size_or_observations\": \"84 tumor-bearing mice\",\n      \"description\": \"Matched control groups included vaccine-only, ICI-only, and vehicle-treated mice.\"\n    },\n    {\n      \"id\": \"human-retrospective-cohort\",\n      \"label\": \"Retrospective human metastatic cohort\",\n      \"sample_size_or_observations\": \"130 patients\",\n      \"description\": \"Metastatic patients receiving ICI treatment, analyzed by prior SARS-CoV-2 mRNA vaccination status.\"\n    },\n    {\n      \"id\": \"human-vaccinated-subgroup\",\n      \"label\": \"Vaccinated human subgroup\",\n      \"sample_size_or_observations\": \"43 patients\",\n      \"description\": \"Subset of the retrospective cohort with documented prior SARS-CoV-2 mRNA vaccination.\"\n    },\n    {\n      \"id\": \"human-unvaccinated-subgroup\",\n      \"label\": \"Unvaccinated human subgroup\",\n      \"sample_size_or_observations\": \"87 patients\",\n      \"description\": \"Comparison subgroup in the human retrospective arm without prior SARS-CoV-2 mRNA vaccination.\"\n    }\n  ],\n  \"major_limitations\": [\n    \"The human analysis is retrospective and non-randomized, so residual confounding is likely.\",\n    \"Vaccination timing relative to ICI initiation varied across patients in the retrospective cohort.\",\n    \"Tumor-type mixture and treatment-history heterogeneity reduce direct causal interpretation.\",\n    \"Mouse model effects may not translate one-to-one to all human tumors.\",\n    \"Some mechanistic readouts were strongest in specific models rather than uniformly across settings.\"\n  ]\n}"
            },
            "output": "Successfully wrote file: output/study_overview.json",
            "callId": "call_7mCcnqvFVEk2lj34HwixcNIT"
          }
        ],
        "usage": {
          "promptTokens": 5422,
          "cachedTokens": 2176,
          "responseTokens": 639,
          "thinkingTokens": 2529,
          "totalTokens": 8590
        },
        "costUsd": 0.0072019
      },
      {
        "step": 7,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/quantitative_findings.json",
              "content": "{\n  \"findings\": [\n    {\n      \"id\": \"Q01\",\n      \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\n      \"value\": \"62.3%\",\n      \"comparator_or_baseline\": \"37.3%\",\n      \"interpretation\": \"Broader antigen display after intratumoral mRNA vaccination\",\n      \"evidence_line_refs\": [\"L28\"]\n    },\n    {\n      \"id\": \"Q02\",\n      \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\n      \"value\": \"40.6%\",\n      \"n\": \"20.6%\"\n      \"comparator_or_baseline\": \"20.6%\",\n      \"interpretation\": \"Strong expansion of MHC-I-presented landscape\",\n      \"evidence_line_refs\": [\"L29\"]\n    },\n    {\n      \"id\": \"Q03\",\n      \"metric\": \"Retrospective human survival comparison p-value\",\n      \"value\": \"p=0.01\",\n      \"comparator_or_baseline\": \"N/A\",\n      \"interpretation\": \"Vaccinated subgroup had improved survival under ICI treatment\",\n      \"evidence_line_refs\": [\"L30\"]\n    },\n    {\n      \"id\": \"Q04\",\n      \"metric\": \"Type I interferon response score\",\n      \"value\": \"3.1 normalized units\",\n      \"comparator_or_baseline\": \"1.0\",\n      \"interpretation\": \"Marked induction after mRNA vaccination in tumors\",\n      \"evidence_line_refs\": [\"L31\"]\n    },\n    {\n      \"id\": \"Q05\",\n      \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\n      \"value\": \"2.4x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Checkpoint axis became more targetable\",\n      \"evidence_line_refs\": [\"L32\"]\n    },\n    {\n      \"id\": \"Q06\",\n      \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\n      \"value\": \"1.8x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Increased immune infiltration with combination therapy\",\n      \"evidence_line_refs\": [\"L33\"]\n    }\n  ],\n  \"controls_or_null_results\": [\n    {\n      \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\n      \"evidence_line_ref\": \"L36\"\n    },\n    {\n      \"statement\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\n      \"evidence_line_ref\": \"L37\"\n    },\n    {\n      \"statement\": \"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\n      \"evidence_line_line_ref\": \"L38\"\n    },\n    {\n      \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n      \"evidence_line_ref\": \"L39\"\n    }\n  ]\n}"
            },
            "output": "Successfully wrote file: output/quantitative_findings.json",
            "callId": "call_LMwA6YM7OA75hp2O0q3cSURb"
          }
        ],
        "usage": {
          "promptTokens": 6080,
          "cachedTokens": 5248,
          "responseTokens": 774,
          "thinkingTokens": 0,
          "totalTokens": 6854
        },
        "costUsd": 0.0018872
      },
      {
        "step": 8,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/claim_audit.json",
              "content": "{\n  \"claims\": [\n    {\n      \"claim_id\": \"C01\",\n      \"claim\": \"Intratumoral mRNA vaccination can sensitize tumors to anti-PD-L1 checkpoint blockade, improving control beyond either treatment alone.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\",\n          \"line_ref\": \"L46\"\n        },\n        {\n          \"quote\": \"Preclinical arm: multiple murine tumor models with intratumoral mRNA vaccine and anti-PD-L1 combinations.\",\n          \"line_ref\": \"L14\"\n        }\n      ],\n      \"caveat\": \"Human evidence is retrospective, and murine results may not generalize to all human tumor types.\"\n    },\n    {\n      \"claim_id\": \"C02\",\n      \"claim\": \"The intervention is associated with broader antigen representation and increased T-cell infiltration in tumors.\n\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Broader antigen display after intratumoral mRNA vaccination\",\",\n          \"line_ref\": \"L28\"\n        },\n        {\n          \"quote\": \"Increased immune infiltration with combination therapy\",\n          \"line_ref\": \"L33\"\n        }\n      ],\n      \"caveat\": \"The quantitative reporting is aggregate and effects may vary by specific model systems.\n\"\n    },\n    {\n      \"claim_id\": \"C03\",\n      \"claim\": \"Type I interferon signaling is mechanistically required for the sensitization effect because its blockade removes benefit.\",\n      \"strength\": \"strong\",\n      \"item\": [\n        {\n          \"quote\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n          \"line_ref\": \"L39\"\n        },\n        {\n          \"quote\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\n          \"line_ref\": \"L42\"\n        }\n      ],\n      \"caveat\": \"Mechanistic causality is strongest in preclinical models and may be partial or context dependent in patients.\"\n    },\n    {\n      \"claim_id\": \"C04\",\n      \"claim\": \"A retrospective cohort analysis suggested improved survival among vaccinated patients receiving ICIs compared with unvaccinated patients.\n\",\n      \"strength\": \"tentative\",\n      \"evidence\": [\n        {\n          \"quote\": \"Retrospective human survival comparison p-value\" ,\n          \"line_ref\": \"L30\"\n        },\n        {\n          \"quote\": \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\n          \"line_ref\": \"L49\"\n        }\n      ],\n      \"caveat\": \"The study is retrospective and non-randomized, with variable vaccination timing and treatment heterogeneity.\n\"\n    }\n  ]\n}"
            },
            "output": "Successfully wrote file: output/claim_audit.json",
            "callId": "call_gOD3HJ400oU7V3FK8VG6PBQz"
          }
        ],
        "usage": {
          "promptTokens": 6876,
          "cachedTokens": 5888,
          "responseTokens": 732,
          "thinkingTokens": 0,
          "totalTokens": 7608
        },
        "costUsd": 0.0018582
      },
      {
        "step": 9,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/public_summary.json",
              "content": "{\n  \"headline\": \"mRNA vaccine injections into tumors may make immune checkpoint therapy work better in some cancers\",\n  \"plain_language_summary\": \"This study looked at whether putting mRNA cancer vaccines directly into tumors could help a known cancer immunotherapy, anti-PD-L1, work better. Researchers tested multiple mouse tumor models and studied patients with metastatic cancer who had or had not previously received SARS-CoV-2 mRNA vaccines before treatment. They found higher fractions of tumor proteins and MHC-I peptides, and increased CD8+ T-cell presence in tumors. The study also reported a survival signal in vaccinated patients receiving ICI therapy, with p=0.01. However, these human findings come from a retrospective non-randomized analysis, and several caveats remain, including timing differences and heterogeneity of patient history and tumor type.\n\nWhile a detailed mechanistic pathway was proposed, it is not yet clear if this can replace randomized trials in humans. The findings are promising but need confirmation before changing clinical care.\n\n\"\n  ,\n  \"what_is_new\": [\n    \"Intratumoral mRNA vaccination may broaden tumor peptide presentation and increase immune-cell infiltration in tumors.\",\n    \"The authors report better alignment between preclinical findings and retrospective human survival signal after ICI treatment in vaccinated patients.\",\n    \"The study points to type I interferon signaling as a key requirement for sensitization through mechanistic experiments including anti-IFNAR1 blockade.\",\n  ],\n  \"why_caution_is_needed\": [\n    \"The human arm is retrospective and non-randomized, so causal claims are limited.\",\n    \"Vaccination timing relative to ICI initiation varied across patients, which can bias survival associations.\",\n    \"Effects differ across mouse models and may not translate equally across human cancers.\",\n    \"Most efficacy evidence is preclinical; mechanistic readouts were strongest in specific models rather than universal.\",\n    \"The trial-like confirmation needed for treatment guidelines has not yet been completed\"\n  ],\n  \"glossary\": [\n    {\n      \"term\": \"mRNA vaccine\",\n      \"definition\": \"A vaccine that uses messenger RNA to instruct cells to make a protein, here delivered into tumors in this study.\",\n    },\n    {\n      \"term\": \"PD-L1\",\n      \"definition\": \"A protein on tumor and immune cells that can suppress immune attack; anti-PD-L1 can block this inhibition.\",\n    },\n    {\n      \"term\": \"T cell\",\n      \"definition\": \"A white blood cell type that can recognize and kill tumor cells when activated.\",\n    },\n    {\n      \"term\": \"Type I interferon\",\n      \"definition\": \"Immune signaling proteins that raise antiviral and anti-tumor responses, including antigen presentation pathways.\",\n    },\n    {\n      \"term\": \"Retrospective study\",\n      \"definition\": \"A study looking back at existing patient data rather than assigning treatment during a new trial.\",\n    }\n  ],\n  \"open_questions\": [\n    \"Which patients and cancer types are most likely to benefit from intratumoural mRNA sensitization.\",\n    \"Can prospective trials reproduce the survival benefit seen in the retrospective vaccinated subgroup?\",\n    \"Do combinations that avoid or reduce side effects preserve the sensitization effect?\",\n    \"Could timing of vaccination relative to ICI start explain much of the observed benefit?\"\n  ]\n}"
            },
            "output": "Successfully wrote file: output/public_summary.json",
            "callId": "call_TCvklA1LSH1PKQHt6q3uPky1"
          }
        ],
        "usage": {
          "promptTokens": 7628,
          "cachedTokens": 6784,
          "responseTokens": 789,
          "thinkingTokens": 0,
          "totalTokens": 8417
        },
        "costUsd": 0.0019586
      },
      {
        "step": 10,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/study_overview.json",
              "offset": 0,
              "limit": 400
            },
            "output": "L1: {\nL2:   \"paper\": {\nL3:     \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\nL4:     \"doi\": \"10.1038/s41586-025-09006-8\",\nL5:     \"publication_year\": 2025,\nL6:     \"domain\": \"oncology-immunology\",\nL7:     \"study_type\": \"preclinical+retrospective\"\nL8:   },\nL9:   \"core_question\": \"Can intratumoral mRNA vaccination sensitize tumors to checkpoint blockade by improving antigen presentation and immune activation?\",\nL10:   \"datasets_or_cohorts\": [\nL11:     {\nL12:       \"id\": \"mouse-efficacy-combination\",\nL13:       \"label\": \"Mouse efficacy cohort\",\nL14:       \"sample_size_or_observations\": \"78 tumor-bearing mice\",\nL15:       \"description\": \"Preclinical arm with intratumoral mRNA vaccine plus anti-PD-L1, pooled across repeat experiments.\"\nL16:     },\nL17:     {\nL18:       \"id\": \"mouse-control-cohort\",\nL19:       \"label\": \"Mouse control arm\",\nL20:       \"sample_size_or_observations\": \"84 tumor-bearing mice\",\nL21:       \"description\": \"Matched control groups included vaccine-only, ICI-only, and vehicle-treated mice.\"\nL22:     },\nL23:     {\nL24:       \"id\": \"human-retrospective-cohort\",\nL25:       \"label\": \"Retrospective human metastatic cohort\",\nL26:       \"sample_size_or_observations\": \"130 patients\",\nL27:       \"description\": \"Metastatic patients receiving ICI treatment, analyzed by prior SARS-CoV-2 mRNA vaccination status.\"\nL28:     },\nL29:     {\nL30:       \"id\": \"human-vaccinated-subgroup\",\nL31:       \"label\": \"Vaccinated human subgroup\",\nL32:       \"sample_size_or_observations\": \"43 patients\",\nL33:       \"description\": \"Subset of the retrospective cohort with documented prior SARS-CoV-2 mRNA vaccination.\"\nL34:     },\nL35:     {\nL36:       \"id\": \"human-unvaccinated-subgroup\",\nL37:       \"label\": \"Unvaccinated human subgroup\",\nL38:       \"sample_size_or_observations\": \"87 patients\",\nL39:       \"description\": \"Comparison subgroup in the human retrospective arm without prior SARS-CoV-2 mRNA vaccination.\"\nL40:     }\nL41:   ],\nL42:   \"major_limitations\": [\nL43:     \"The human analysis is retrospective and non-randomized, so residual confounding is likely.\",\nL44:     \"Vaccination timing relative to ICI initiation varied across patients in the retrospective cohort.\",\nL45:     \"Tumor-type mixture and treatment-history heterogeneity reduce direct causal interpretation.\",\nL46:     \"Mouse model effects may not translate one-to-one to all human tumors.\",\nL47:     \"Some mechanistic readouts were strongest in specific models rather than uniformly across settings.\"\nL48:   ]\nL49: }",
            "callId": "call_6WA7awnNTcbD6MQeXHJtm7vZ"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/quantitative_findings.json",
              "offset": 0,
              "limit": 500
            },
            "output": "L1: {\nL2:   \"findings\": [\nL3:     {\nL4:       \"id\": \"Q01\",\nL5:       \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\nL6:       \"value\": \"62.3%\",\nL7:       \"comparator_or_baseline\": \"37.3%\",\nL8:       \"interpretation\": \"Broader antigen display after intratumoral mRNA vaccination\",\nL9:       \"evidence_line_refs\": [\"L28\"]\nL10:     },\nL11:     {\nL12:       \"id\": \"Q02\",\nL13:       \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\nL14:       \"value\": \"40.6%\",\nL15:       \"n\": \"20.6%\"\nL16:       \"comparator_or_baseline\": \"20.6%\",\nL17:       \"interpretation\": \"Strong expansion of MHC-I-presented landscape\",\nL18:       \"evidence_line_refs\": [\"L29\"]\nL19:     },\nL20:     {\nL21:       \"id\": \"Q03\",\nL22:       \"metric\": \"Retrospective human survival comparison p-value\",\nL23:       \"value\": \"p=0.01\",\nL24:       \"comparator_or_baseline\": \"N/A\",\nL25:       \"interpretation\": \"Vaccinated subgroup had improved survival under ICI treatment\",\nL26:       \"evidence_line_refs\": [\"L30\"]\nL27:     },\nL28:     {\nL29:       \"id\": \"Q04\",\nL30:       \"metric\": \"Type I interferon response score\",\nL31:       \"value\": \"3.1 normalized units\",\nL32:       \"comparator_or_baseline\": \"1.0\",\nL33:       \"interpretation\": \"Marked induction after mRNA vaccination in tumors\",\nL34:       \"evidence_line_refs\": [\"L31\"]\nL35:     },\nL36:     {\nL37:       \"id\": \"Q05\",\nL38:       \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\nL39:       \"value\": \"2.4x\",\nL40:       \"comparator_or_baseline\": \"1.0x\",\nL41:       \"interpretation\": \"Checkpoint axis became more targetable\",\nL42:       \"evidence_line_refs\": [\"L32\"]\nL43:     },\nL44:     {\nL45:       \"id\": \"Q06\",\nL46:       \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\nL47:       \"value\": \"1.8x\",\nL48:       \"comparator_or_baseline\": \"1.0x\",\nL49:       \"interpretation\": \"Increased immune infiltration with combination therapy\",\nL50:       \"evidence_line_refs\": [\"L33\"]\nL51:     }\nL52:   ],\nL53:   \"controls_or_null_results\": [\nL54:     {\nL55:       \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\nL56:       \"evidence_line_ref\": \"L36\"\nL57:     },\nL58:     {\nL59:       \"statement\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\nL60:       \"evidence_line_ref\": \"L37\"\nL61:     },\nL62:     {\nL63:       \"statement\": \"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\nL64:       \"evidence_line_line_ref\": \"L38\"\nL65:     },\nL66:     {\nL67:       \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\nL68:       \"evidence_line_ref\": \"L39\"\nL69:     }\nL70:   ]\nL71: }",
            "callId": "call_EKtWyFYO30LCnYB8meO7C8Rt"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/claim_audit.json",
              "offset": 0,
              "limit": 700
            },
            "output": "L1: {\nL2:   \"claims\": [\nL3:     {\nL4:       \"claim_id\": \"C01\",\nL5:       \"claim\": \"Intratumoral mRNA vaccination can sensitize tumors to anti-PD-L1 checkpoint blockade, improving control beyond either treatment alone.\",\nL6:       \"strength\": \"moderate\",\nL7:       \"evidence\": [\nL8:         {\nL9:           \"quote\": \"Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\",\nL10:           \"line_ref\": \"L46\"\nL11:         },\nL12:         {\nL13:           \"quote\": \"Preclinical arm: multiple murine tumor models with intratumoral mRNA vaccine and anti-PD-L1 combinations.\",\nL14:           \"line_ref\": \"L14\"\nL15:         }\nL16:       ],\nL17:       \"caveat\": \"Human evidence is retrospective, and murine results may not generalize to all human tumor types.\"\nL18:     },\nL19:     {\nL20:       \"claim_id\": \"C02\",\nL21:       \"claim\": \"The intervention is associated with broader antigen representation and increased T-cell infiltration in tumors.\nL22: \",\nL23:       \"strength\": \"strong\",\nL24:       \"evidence\": [\nL25:         {\nL26:           \"quote\": \"Broader antigen display after intratumoral mRNA vaccination\",\",\nL27:           \"line_ref\": \"L28\"\nL28:         },\nL29:         {\nL30:           \"quote\": \"Increased immune infiltration with combination therapy\",\nL31:           \"line_ref\": \"L33\"\nL32:         }\nL33:       ],\nL34:       \"caveat\": \"The quantitative reporting is aggregate and effects may vary by specific model systems.\nL35: \"\nL36:     },\nL37:     {\nL38:       \"claim_id\": \"C03\",\nL39:       \"claim\": \"Type I interferon signaling is mechanistically required for the sensitization effect because its blockade removes benefit.\",\nL40:       \"strength\": \"strong\",\nL41:       \"item\": [\nL42:         {\nL43:           \"quote\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\nL44:           \"line_ref\": \"L39\"\nL45:         },\nL46:         {\nL47:           \"quote\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\nL48:           \"line_ref\": \"L42\"\nL49:         }\nL50:       ],\nL51:       \"caveat\": \"Mechanistic causality is strongest in preclinical models and may be partial or context dependent in patients.\"\nL52:     },\nL53:     {\nL54:       \"claim_id\": \"C04\",\nL55:       \"claim\": \"A retrospective cohort analysis suggested improved survival among vaccinated patients receiving ICIs compared with unvaccinated patients.\nL56: \",\nL57:       \"strength\": \"tentative\",\nL58:       \"evidence\": [\nL59:         {\nL60:           \"quote\": \"Retrospective human survival comparison p-value\" ,\nL61:           \"line_ref\": \"L30\"\nL62:         },\nL63:         {\nL64:           \"quote\": \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\nL65:           \"line_ref\": \"L49\"\nL66:         }\nL67:       ],\nL68:       \"caveat\": \"The study is retrospective and non-randomized, with variable vaccination timing and treatment heterogeneity.\nL69: \"\nL70:     }\nL71:   ]\nL72: }",
            "callId": "call_nP11SVSEbrBivSSLR2RKlSQs"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/public_summary.json",
              "offset": 0,
              "limit": 900
            },
            "output": "L1: {\nL2:   \"headline\": \"mRNA vaccine injections into tumors may make immune checkpoint therapy work better in some cancers\",\nL3:   \"plain_language_summary\": \"This study looked at whether putting mRNA cancer vaccines directly into tumors could help a known cancer immunotherapy, anti-PD-L1, work better. Researchers tested multiple mouse tumor models and studied patients with metastatic cancer who had or had not previously received SARS-CoV-2 mRNA vaccines before treatment. They found higher fractions of tumor proteins and MHC-I peptides, and increased CD8+ T-cell presence in tumors. The study also reported a survival signal\nL4: \nL5: While a detailed mechanistic pathway was proposed, it is not yet clear if this can replace randomized trials in humans. The findings are promising but need confirmation before changing clinical care.\nL6: \nL7: \"\nL8:   ,\nL9:   \"what_is_new\": [\nL10:     \"Intratumoral mRNA vaccination may broaden tumor peptide presentation and increase immune-cell infiltration in tumors.\",\nL11:     \"The authors report better alignment between preclinical findings and retrospective human survival signal after ICI treatment in vaccinated patients.\",\nL12:     \"The study points to type I interferon signaling as a key requirement for sensitization through mechanistic experiments including anti-IFNAR1 blockade.\",\nL13:   ],\nL14:   \"why_caution_is_needed\": [\nL15:     \"The human arm is retrospective and non-randomized, so causal claims are limited.\",\nL16:     \"Vaccination timing relative to ICI initiation varied across patients, which can bias survival associations.\",\nL17:     \"Effects differ across mouse models and may not translate equally across human cancers.\",\nL18:     \"Most efficacy evidence is preclinical; mechanistic readouts were strongest in specific models rather than universal.\",\nL19:     \"The trial-like confirmation needed for treatment guidelines has not yet been completed\"\nL20:   ],\nL21:   \"glossary\": [\nL22:     {\nL23:       \"term\": \"mRNA vaccine\",\nL24:       \"definition\": \"A vaccine that uses messenger RNA to instruct cells to make a protein, here delivered into tumors in this study.\",\nL25:     },\nL26:     {\nL27:       \"term\": \"PD-L1\",\nL28:       \"definition\": \"A protein on tumor and immune cells that can suppress immune attack; anti-PD-L1 can block this inhibition.\",\nL29:     },\nL30:     {\nL31:       \"term\": \"T cell\",\nL32:       \"definition\": \"A white blood cell type that can recognize and kill tumor cells when activated.\",\nL33:     },\nL34:     {\nL35:       \"term\": \"Type I interferon\",\nL36:       \"definition\": \"Immune signaling proteins that raise antiviral and anti-tumor responses, including antigen presentation pathways.\",\nL37:     },\nL38:     {\nL39:       \"term\": \"Retrospective study\",\nL40:       \"definition\": \"A study looking back at existing patient data rather than assigning treatment during a new trial.\",\nL41:     }\nL42:   ],\nL43:   \"open_questions\": [\nL44:     \"Which patients and cancer types are most likely to benefit from intratumoural mRNA sensitization.\",\nL45:     \"Can prospective trials reproduce the survival benefit seen in the retrospective vaccinated subgroup?\",\nL46:     \"Do combinations that avoid or reduce side effects preserve the sensitization effect?\",\nL47:     \"Could timing of vaccination relative to ICI start explain much of the observed benefit?\"\nL48:   ]\nL49: }",
            "callId": "call_AvMQsEZZYtEwXwkPbV3sYLL0"
          }
        ],
        "usage": {
          "promptTokens": 8436,
          "cachedTokens": 7424,
          "responseTokens": 133,
          "thinkingTokens": 257,
          "totalTokens": 8826
        },
        "costUsd": 0.0012186
      },
      {
        "step": 11,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/study_overview.json",
              "content": "{\n  \"paper\": {\n    \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\n    \"doi\": \"10.1038/s41586-025-09006-8\",\n    \"publication_year\": 2025,\n    \"domain\": \"oncology-immunology\",\n    \"study_type\": \"preclinical+retrospective\"\n  },\n  \"core_question\": \"Can intratumoral mRNA vaccination sensitize tumors to immune checkpoint blockade by improving antigen presentation and immune activation?\",\n  \"datasets_or_cohorts\": [\n    {\n      \"id\": \"mouse-efficacy-combination\",\n      \"label\": \"Mouse efficacy cohort\",\n      \"sample_size_or_observations\": \"78 tumor-bearing mice\",\n      \"description\": \"Preclinical arm across multiple murine tumor models combining intratumoral mRNA vaccine with anti-PD-L1, pooled across repeat experiments.\"\n    },\n    {\n      \"id\": \"mouse-control-cohort\",\n      \"label\": \"Mouse control cohort\",\n      \"sample_size_or_observations\": \"84 tumor-bearing mice\",\n      \"description\": \"Matched control setting including vaccine-only, ICI-only, and vehicle groups across the murine experiments.\"\n    },\n    {\n      \"id\": \"human-retrospective-cohort\",\n      \"label\": \"Retrospective metastatic cohort\",\n      \"sample_size_or_observations\": \"130 patients\",\n      \"description\": \"Retrospective cohort of metastatic patients receiving ICI treatment, stratified by prior SARS-CoV-2 mRNA vaccination status.\"\n    },\n    {\n      \"id\": \"human-vaccinated-subgroup\",\n      \"label\": \"Vaccinated subgroup\",\n      \"sample_size_or_observations\": \"43 patients\",\n      \"description\": \"Subgroup of the retrospective cohort with prior SARS-CoV-2 mRNA vaccination.\"\n    },\n    {\n      \"id\": \"human-unvaccinated-subgroup\",\n      \"label\": \"Unvaccinated subgroup\",\n      \"sample_size_or_observations\": \"87 patients\",\n      \"description\": \"Subgroup of the retrospective cohort without prior SARS-CoV-2 mRNA vaccination.\"\n    }\n  ],\n  \"major_limitations\": [\n    \"The human analysis is retrospective and non-randomized, so residual confounding is likely.\",\n    \"Vaccination timing relative to ICI initiation varied across patients.\",\n    \"Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\",\n    \"Mouse model effects may not map one-to-one to all human tumors.\",\n    \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all settings.\"\n  ]\n}"
            },
            "output": "Successfully wrote file: output/study_overview.json",
            "callId": "call_8wGZUJ3EuKkdR9GROO5j5ZSF"
          }
        ],
        "usage": {
          "promptTokens": 11734,
          "cachedTokens": 8320,
          "responseTokens": 648,
          "thinkingTokens": 1488,
          "totalTokens": 13870
        },
        "costUsd": 0.0053335
      },
      {
        "step": 12,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/quantitative_findings.json",
              "content": "{\n  \"findings\": [\n    {\n      \"id\": \"Q01\",\n      \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\n      \"value\": \"62.3%\",\n      \"comparator_or_baseline\": \"37.3%\",\n      \"interpretation\": \"Broader antigen display after intratumoral mRNA vaccination\",\n      \"evidence_line_refs\": [\"L28\"]\n    },\n    {\n      \"id\": \"Q02\",\n      \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\n      \"value\": \"40.6%\",\n      \"comparator_or_baseline\": \"20.6%\",\n      \"interpretation\": \"Strong expansion of MHC-I-presented landscape\",\n      \"evidence_line_refs\": [\"L29\"]\n    },\n    {\n      \"id\": \"Q03\",\n      \"metric\": \"Retrospective human survival comparison p-value\",\n      \"value\": \"p=0.01\",\n      \"comparator_or_baseline\": \"N/A\",\n      \"interpretation\": \"Vaccinated subgroup had improved survival under ICI treatment\",\n      \"evidence_line_refs\": [\"L30\"]\n    },\n    {\n      \"id\": \"Q04\",\n      \"metric\": \"Type I interferon response score (normalized units)\",\n      \"value\": \"3.1\",\n      \"comparator_or_baseline\": \"1.0\",\n      \"interpretation\": \"Marked induction after mRNA vaccination in tumors\",\n      \"evidence_line_refs\": [\"L31\"]\n    },\n    {\n      \"id\": \"Q05\",\n      \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\n      \"value\": \"2.4x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Checkpoint axis became more targetable\",\n      \"evidence_line_refs\": [\"L32\"]\n    },\n    {\n      \"id\": \"Q06\",\n      \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\n      \"value\": \"1.8x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Increased immune infiltration with combination therapy\",\n      \"evidence_line_refs\": [\"L33\"]\n    }\n  ],\n  \"controls_or_null_results\": [\n    {\n      \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\n      \"evidence_line_ref\": \"L36\"\n    },\n    {\n      \"statement\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\n      \"evidence_line_ref\": \"L37\"\n    },\n    {\n      \"statement\": \"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\n      \"evidence_line_ref\": \"L38\"\n    },\n    {\n      \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n      \"evidence_line_ref\": \"L39\"\n    }\n  ]\n}"
            },
            "output": "Successfully wrote file: output/quantitative_findings.json",
            "callId": "call_4ssJFsEswFGonm3lAmsuTgop"
          }
        ],
        "usage": {
          "promptTokens": 12401,
          "cachedTokens": 11648,
          "responseTokens": 765,
          "thinkingTokens": 0,
          "totalTokens": 13166
        },
        "costUsd": 0.00200945
      },
      {
        "step": 13,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/claim_audit.json",
              "offset": 0,
              "limit": 1200
            },
            "output": "L1: {\nL2:   \"claims\": [\nL3:     {\nL4:       \"claim_id\": \"C01\",\nL5:       \"claim\": \"Intratumoral mRNA vaccination can sensitize tumors to anti-PD-L1 checkpoint blockade, improving control beyond either treatment alone.\",\nL6:       \"strength\": \"moderate\",\nL7:       \"evidence\": [\nL8:         {\nL9:           \"quote\": \"Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\",\nL10:           \"line_ref\": \"L46\"\nL11:         },\nL12:         {\nL13:           \"quote\": \"Preclinical arm: multiple murine tumor models with intratumoral mRNA vaccine and anti-PD-L1 combinations.\",\nL14:           \"line_ref\": \"L14\"\nL15:         }\nL16:       ],\nL17:       \"caveat\": \"Human evidence is retrospective, and murine results may not generalize to all human tumor types.\"\nL18:     },\nL19:     {\nL20:       \"claim_id\": \"C02\",\nL21:       \"claim\": \"The intervention is associated with broader antigen representation and increased T-cell infiltration in tumors.\nL22: \",\nL23:       \"strength\": \"strong\",\nL24:       \"evidence\": [\nL25:         {\nL26:           \"quote\": \"Broader antigen display after intratumoral mRNA vaccination\",\",\nL27:           \"line_ref\": \"L28\"\nL28:         },\nL29:         {\nL30:           \"quote\": \"Increased immune infiltration with combination therapy\",\nL31:           \"line_ref\": \"L33\"\nL32:         }\nL33:       ],\nL34:       \"caveat\": \"The quantitative reporting is aggregate and effects may vary by specific model systems.\nL35: \"\nL36:     },\nL37:     {\nL38:       \"claim_id\": \"C03\",\nL39:       \"claim\": \"Type I interferon signaling is mechanistically required for the sensitization effect because its blockade removes benefit.\",\nL40:       \"strength\": \"strong\",\nL41:       \"item\": [\nL42:         {\nL43:           \"quote\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\nL44:           \"line_ref\": \"L39\"\nL45:         },\nL46:         {\nL47:           \"quote\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\nL48:           \"line_ref\": \"L42\"\nL49:         }\nL50:       ],\nL51:       \"caveat\": \"Mechanistic causality is strongest in preclinical models and may be partial or context dependent in patients.\"\nL52:     },\nL53:     {\nL54:       \"claim_id\": \"C04\",\nL55:       \"claim\": \"A retrospective cohort analysis suggested improved survival among vaccinated patients receiving ICIs compared with unvaccinated patients.\nL56: \",\nL57:       \"strength\": \"tentative\",\nL58:       \"evidence\": [\nL59:         {\nL60:           \"quote\": \"Retrospective human survival comparison p-value\" ,\nL61:           \"line_ref\": \"L30\"\nL62:         },\nL63:         {\nL64:           \"quote\": \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\nL65:           \"line_ref\": \"L49\"\nL66:         }\nL67:       ],\nL68:       \"caveat\": \"The study is retrospective and non-randomized, with variable vaccination timing and treatment heterogeneity.\nL69: \"\nL70:     }\nL71:   ]\nL72: }",
            "callId": "call_lVaUDwRIAHvlD1VXikyQhNEh"
          }
        ],
        "usage": {
          "promptTokens": 13188,
          "cachedTokens": 12288,
          "responseTokens": 35,
          "thinkingTokens": 295,
          "totalTokens": 13518
        },
        "costUsd": 0.0011922
      },
      {
        "step": 14,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/claim_audit.json",
              "content": "{\n  \"claims\": [\n    {\n      \"claim_id\": \"C01\",\n      \"claim\": \"Intratumoral mRNA vaccination can sensitize tumors to anti-PD-L1 checkpoint blockade and improve control when combined.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\",\n          \"line_ref\": \"L46\"\n        },\n        {\n          \"quote\": \"Preclinical arm: multiple murine tumor models with intratumoral mRNA vaccine and anti-PD-L1 combinations.\",\n          \"line_ref\": \"L14\"\n        }\n      ],\n      \"caveat\": \"The human association is observational, and preclinical efficacy may not generalize to all human tumor settings.\"\n    },\n    {\n      \"claim_id\": \"C02\",\n      \"claim\": \"mRNA vaccination is associated with a broader antigenic landscape and greater immune-cell presence in tumors.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Broader antigen display after intratumoral mRNA vaccination\",\n          \"line_ref\": \"L28\"\n        },\n        {\n          \"quote\": \"Increased immune infiltration with combination therapy\",\n          \"line_ref\": \"L33\"\n        }\n      ],\n      \"caveat\": \"These quantitative readouts are summary values and mechanistic effects were not uniformly identical across all models.\"\n    },\n    {\n      \"claim_id\": \"C03\",\n      \"claim\": \"Type I interferon signaling is a required mechanism in this sensitization process in the reported experiments.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n          \"line_ref\": \"L39\"\n        },\n        {\n          \"quote\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\n          \"line_ref\": \"L42\"\n        }\n      ],\n      \"caveat\": \"Causality is best supported in mechanistic mouse experiments and has not been proven as the dominant driver clinically.\"\n    },\n    {\n      \"claim_id\": \"C04\",\n      \"claim\": \"Retrospective human data suggest a survival advantage for vaccinated patients receiving immune checkpoint blockade.\",\n      \"strength\": \"tentative\",\n      \"evidence\": [\n        {\n          \"quote\": \"Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment\",\n          \"line_ref\": \"L30\"\n        },\n        {\n          \"quote\": \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\n          \"line_ref\": \"L49\"\n        }\n      ],\n      \"caveat\": \"Causal interpretation is limited by non-randomized design, variable vaccination timing, and heterogeneity in tumor types and treatment history.\"\n    }\n  ]\n}"
            },
            "output": "Successfully wrote file: output/claim_audit.json",
            "callId": "call_Aj1DGls8vF26ipk0AlOLEXfN"
          }
        ],
        "usage": {
          "promptTokens": 14047,
          "cachedTokens": 13056,
          "responseTokens": 761,
          "thinkingTokens": 2476,
          "totalTokens": 17284
        },
        "costUsd": 0.0070481499999999996
      },
      {
        "step": 15,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/public_summary.json",
              "offset": 0,
              "limit": 1000
            },
            "output": "L1: {\nL2:   \"headline\": \"mRNA vaccine injections into tumors may make immune checkpoint therapy work better in some cancers\",\nL3:   \"plain_language_summary\": \"This study looked at whether putting mRNA cancer vaccines directly into tumors could help a known cancer immunotherapy, anti-PD-L1, work better. Researchers tested multiple mouse tumor models and studied patients with metastatic cancer who had or had not previously received SARS-CoV-2 mRNA vaccines before treatment. They found higher fractions of tumor proteins and MHC-I peptides, and increased CD8+ T-cell presence in tumors. The study also reported a survival signal\nL4: \nL5: While a detailed mechanistic pathway was proposed, it is not yet clear if this can replace randomized trials in humans. The findings are promising but need confirmation before changing clinical care.\nL6: \nL7: \"\nL8:   ,\nL9:   \"what_is_new\": [\nL10:     \"Intratumoral mRNA vaccination may broaden tumor peptide presentation and increase immune-cell infiltration in tumors.\",\nL11:     \"The authors report better alignment between preclinical findings and retrospective human survival signal after ICI treatment in vaccinated patients.\",\nL12:     \"The study points to type I interferon signaling as a key requirement for sensitization through mechanistic experiments including anti-IFNAR1 blockade.\",\nL13:   ],\nL14:   \"why_caution_is_needed\": [\nL15:     \"The human arm is retrospective and non-randomized, so causal claims are limited.\",\nL16:     \"Vaccination timing relative to ICI initiation varied across patients, which can bias survival associations.\",\nL17:     \"Effects differ across mouse models and may not translate equally across human cancers.\",\nL18:     \"Most efficacy evidence is preclinical; mechanistic readouts were strongest in specific models rather than universal.\",\nL19:     \"The trial-like confirmation needed for treatment guidelines has not yet been completed\"\nL20:   ],\nL21:   \"glossary\": [\nL22:     {\nL23:       \"term\": \"mRNA vaccine\",\nL24:       \"definition\": \"A vaccine that uses messenger RNA to instruct cells to make a protein, here delivered into tumors in this study.\",\nL25:     },\nL26:     {\nL27:       \"term\": \"PD-L1\",\nL28:       \"definition\": \"A protein on tumor and immune cells that can suppress immune attack; anti-PD-L1 can block this inhibition.\",\nL29:     },\nL30:     {\nL31:       \"term\": \"T cell\",\nL32:       \"definition\": \"A white blood cell type that can recognize and kill tumor cells when activated.\",\nL33:     },\nL34:     {\nL35:       \"term\": \"Type I interferon\",\nL36:       \"definition\": \"Immune signaling proteins that raise antiviral and anti-tumor responses, including antigen presentation pathways.\",\nL37:     },\nL38:     {\nL39:       \"term\": \"Retrospective study\",\nL40:       \"definition\": \"A study looking back at existing patient data rather than assigning treatment during a new trial.\",\nL41:     }\nL42:   ],\nL43:   \"open_questions\": [\nL44:     \"Which patients and cancer types are most likely to benefit from intratumoural mRNA sensitization.\",\nL45:     \"Can prospective trials reproduce the survival benefit seen in the retrospective vaccinated subgroup?\",\nL46:     \"Do combinations that avoid or reduce side effects preserve the sensitization effect?\",\nL47:     \"Could timing of vaccination relative to ICI start explain much of the observed benefit?\"\nL48:   ]\nL49: }",
            "callId": "call_FTfSxZIM9igFuK1pngOheGb1"
          }
        ],
        "usage": {
          "promptTokens": 14827,
          "cachedTokens": 13952,
          "responseTokens": 33,
          "thinkingTokens": 176,
          "totalTokens": 15036
        },
        "costUsd": 0.00098555
      },
      {
        "step": 16,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/study_overview.json",
              "offset": 0,
              "limit": 500
            },
            "output": "L1: {\nL2:   \"paper\": {\nL3:     \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\nL4:     \"doi\": \"10.1038/s41586-025-09006-8\",\nL5:     \"publication_year\": 2025,\nL6:     \"domain\": \"oncology-immunology\",\nL7:     \"study_type\": \"preclinical+retrospective\"\nL8:   },\nL9:   \"core_question\": \"Can intratumoral mRNA vaccination sensitize tumors to immune checkpoint blockade by improving antigen presentation and immune activation?\",\nL10:   \"datasets_or_cohorts\": [\nL11:     {\nL12:       \"id\": \"mouse-efficacy-combination\",\nL13:       \"label\": \"Mouse efficacy cohort\",\nL14:       \"sample_size_or_observations\": \"78 tumor-bearing mice\",\nL15:       \"description\": \"Preclinical arm across multiple murine tumor models combining intratumoral mRNA vaccine with anti-PD-L1, pooled across repeat experiments.\"\nL16:     },\nL17:     {\nL18:       \"id\": \"mouse-control-cohort\",\nL19:       \"label\": \"Mouse control cohort\",\nL20:       \"sample_size_or_observations\": \"84 tumor-bearing mice\",\nL21:       \"description\": \"Matched control setting including vaccine-only, ICI-only, and vehicle groups across the murine experiments.\"\nL22:     },\nL23:     {\nL24:       \"id\": \"human-retrospective-cohort\",\nL25:       \"label\": \"Retrospective metastatic cohort\",\nL26:       \"sample_size_or_observations\": \"130 patients\",\nL27:       \"description\": \"Retrospective cohort of metastatic patients receiving ICI treatment, stratified by prior SARS-CoV-2 mRNA vaccination status.\"\nL28:     },\nL29:     {\nL30:       \"id\": \"human-vaccinated-subgroup\",\nL31:       \"label\": \"Vaccinated subgroup\",\nL32:       \"sample_size_or_observations\": \"43 patients\",\nL33:       \"description\": \"Subgroup of the retrospective cohort with prior SARS-CoV-2 mRNA vaccination.\"\nL34:     },\nL35:     {\nL36:       \"id\": \"human-unvaccinated-subgroup\",\nL37:       \"label\": \"Unvaccinated subgroup\",\nL38:       \"sample_size_or_observations\": \"87 patients\",\nL39:       \"description\": \"Subgroup of the retrospective cohort without prior SARS-CoV-2 mRNA vaccination.\"\nL40:     }\nL41:   ],\nL42:   \"major_limitations\": [\nL43:     \"The human analysis is retrospective and non-randomized, so residual confounding is likely.\",\nL44:     \"Vaccination timing relative to ICI initiation varied across patients.\",\nL45:     \"Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\",\nL46:     \"Mouse model effects may not map one-to-one to all human tumors.\",\nL47:     \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all settings.\"\nL48:   ]\nL49: }",
            "callId": "call_EhS6NNCZ8TWKdqjZMWMAf4Eh"
          }
        ],
        "usage": {
          "promptTokens": 15644,
          "cachedTokens": 14720,
          "responseTokens": 34,
          "thinkingTokens": 754,
          "totalTokens": 16432
        },
        "costUsd": 0.002175
      },
      {
        "step": 17,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/public_summary.json",
              "content": "{\n  \"headline\": \"mRNA vaccine injections into tumors may make immune checkpoint therapy work better in some cancers\",\n  \"plain_language_summary\": \"This study explored whether delivering SARS-CoV-2 mRNA-based vaccines directly into tumors could improve responses to anti-PD-L1. In mouse studies, the combination was linked to stronger antitumor signals such as broader antigen display and higher immune-cell presence. In a retrospective cohort of 130 metastatic patients (43 vaccinated and 87 unvaccinated), vaccinated patients had a reported survival association with ICI treatment (p=0.01). However, results are preliminary for humans because the cohort is retrospective and non-randomized, with varying vaccine timing and diverse cancers and treatment histories. Prospective trials are still needed before changing clinical practice.\n\",\n  \"what_is_new\": [\n    \"Intratumoral mRNA vaccination may broaden tumor peptide presentation and increase immune-cell infiltration.\",\n    \"The work links a larger tumor immunopeptidome and MHC-I repertoire with a potential benefit from adding anti-PD-L1.\",\n    \"Type I interferon signaling appears necessary for full sensitization in mechanistic experiments, with anti-IFNAR1 blocking the effect.\"\n  ],\n  \"why_caution_is_needed\": [\n    \"The human arm is retrospective and non-randomized, so causal claims are limited.\",\n    \"Vaccination timing relative to ICI initiation varied across patients and could bias outcome comparisons.\",\n    \"Not all mechanistic effects were universal across model systems, and mouse findings may not fully translate to humans.\",\n    \"Residual confounding and tumor heterogeneity may explain part of the observed survival association.\",\n    \"The study does not yet provide randomized clinical trial-level evidence for changing treatment protocols.\"\n  ],\n  \"glossary\": [\n    {\n      \"term\": \"mRNA vaccine\",\n      \"definition\": \"A vaccine using messenger RNA to instruct cells to produce a protein; here delivered into the tumor to stimulate immunity.\"\n    },\n    {\n      \"term\": \"PD-L1\",\n      \"definition\": \"A protein that can suppress immune attack on tumors; anti-PD-L1 antibodies block this suppressive signal.\"\n    },\n    {\n      \"term\": \"MHC-I\",\n      \"definition\": \"A molecule on cells that presents protein fragments to CD8 T cells, helping immune recognition of targets.\"\n    },\n    {\n      \"term\": \"Interferon\",\n      \"definition\": \"A family of immune signaling molecules that amplify antiviral and anti-tumor responses, including antigen presentation.\"\n    },\n    {\n      \"term\": \"Retrospective study\",\n      \"definition\": \"A study that analyzes existing records rather than assigning treatments prospectively in a new trial.\"\n    }\n  ],\n  \"open_questions\": [\n    \"Which patients and cancer types benefit most from intratumoral mRNA priming strategies?\",\n    \"Can prospective randomized trials replicate the human survival signal seen in vaccinated patients?\",\n    \"What is the safest and most effective schedule for combining intratumoral mRNA vaccination with ICI?\",\n    \"Can the observed benefits be maintained while minimizing inflammatory or autoimmune side effects?\"\n  ]\n}"
            },
            "output": "Successfully wrote file: output/public_summary.json",
            "callId": "call_r0vWRiVSa1Z2NVKY2bXoJEcU"
          }
        ],
        "usage": {
          "promptTokens": 16381,
          "cachedTokens": 15488,
          "responseTokens": 742,
          "thinkingTokens": 0,
          "totalTokens": 17123
        },
        "costUsd": 0.00209445
      },
      {
        "step": 18,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/quantitative_findings.json",
              "offset": 0,
              "limit": 400
            },
            "output": "L1: {\nL2:   \"findings\": [\nL3:     {\nL4:       \"id\": \"Q01\",\nL5:       \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\nL6:       \"value\": \"62.3%\",\nL7:       \"comparator_or_baseline\": \"37.3%\",\nL8:       \"interpretation\": \"Broader antigen display after intratumoral mRNA vaccination\",\nL9:       \"evidence_line_refs\": [\"L28\"]\nL10:     },\nL11:     {\nL12:       \"id\": \"Q02\",\nL13:       \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\nL14:       \"value\": \"40.6%\",\nL15:       \"comparator_or_baseline\": \"20.6%\",\nL16:       \"interpretation\": \"Strong expansion of MHC-I-presented landscape\",\nL17:       \"evidence_line_refs\": [\"L29\"]\nL18:     },\nL19:     {\nL20:       \"id\": \"Q03\",\nL21:       \"metric\": \"Retrospective human survival comparison p-value\",\nL22:       \"value\": \"p=0.01\",\nL23:       \"comparator_or_baseline\": \"N/A\",\nL24:       \"interpretation\": \"Vaccinated subgroup had improved survival under ICI treatment\",\nL25:       \"evidence_line_refs\": [\"L30\"]\nL26:     },\nL27:     {\nL28:       \"id\": \"Q04\",\nL29:       \"metric\": \"Type I interferon response score (normalized units)\",\nL30:       \"value\": \"3.1\",\nL31:       \"comparator_or_baseline\": \"1.0\",\nL32:       \"interpretation\": \"Marked induction after mRNA vaccination in tumors\",\nL33:       \"evidence_line_refs\": [\"L31\"]\nL34:     },\nL35:     {\nL36:       \"id\": \"Q05\",\nL37:       \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\nL38:       \"value\": \"2.4x\",\nL39:       \"comparator_or_baseline\": \"1.0x\",\nL40:       \"interpretation\": \"Checkpoint axis became more targetable\",\nL41:       \"evidence_line_refs\": [\"L32\"]\nL42:     },\nL43:     {\nL44:       \"id\": \"Q06\",\nL45:       \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\nL46:       \"value\": \"1.8x\",\nL47:       \"comparator_or_baseline\": \"1.0x\",\nL48:       \"interpretation\": \"Increased immune infiltration with combination therapy\",\nL49:       \"evidence_line_refs\": [\"L33\"]\nL50:     }\nL51:   ],\nL52:   \"controls_or_null_results\": [\nL53:     {\nL54:       \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\nL55:       \"evidence_line_ref\": \"L36\"\nL56:     },\nL57:     {\nL58:       \"statement\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\nL59:       \"evidence_line_ref\": \"L37\"\nL60:     },\nL61:     {\nL62:       \"statement\": \"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\nL63:       \"evidence_line_ref\": \"L38\"\nL64:     },\nL65:     {\nL66:       \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\nL67:       \"evidence_line_ref\": \"L39\"\nL68:     }\nL69:   ]\nL70: }",
            "callId": "call_Ydd27WFphx222wNOAHVWU3Ua"
          }
        ],
        "usage": {
          "promptTokens": 17142,
          "cachedTokens": 16256,
          "responseTokens": 35,
          "thinkingTokens": 231,
          "totalTokens": 17408
        },
        "costUsd": 0.0011599000000000002
      },
      {
        "step": 19,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/claim_audit.json",
              "offset": 0,
              "limit": 700
            },
            "output": "L1: {\nL2:   \"claims\": [\nL3:     {\nL4:       \"claim_id\": \"C01\",\nL5:       \"claim\": \"Intratumoral mRNA vaccination can sensitize tumors to anti-PD-L1 checkpoint blockade and improve control when combined.\",\nL6:       \"strength\": \"moderate\",\nL7:       \"evidence\": [\nL8:         {\nL9:           \"quote\": \"Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\",\nL10:           \"line_ref\": \"L46\"\nL11:         },\nL12:         {\nL13:           \"quote\": \"Preclinical arm: multiple murine tumor models with intratumoral mRNA vaccine and anti-PD-L1 combinations.\",\nL14:           \"line_ref\": \"L14\"\nL15:         }\nL16:       ],\nL17:       \"caveat\": \"The human association is observational, and preclinical efficacy may not generalize to all human tumor settings.\"\nL18:     },\nL19:     {\nL20:       \"claim_id\": \"C02\",\nL21:       \"claim\": \"mRNA vaccination is associated with a broader antigenic landscape and greater immune-cell presence in tumors.\",\nL22:       \"strength\": \"strong\",\nL23:       \"evidence\": [\nL24:         {\nL25:           \"quote\": \"Broader antigen display after intratumoral mRNA vaccination\",\nL26:           \"line_ref\": \"L28\"\nL27:         },\nL28:         {\nL29:           \"quote\": \"Increased immune infiltration with combination therapy\",\nL30:           \"line_ref\": \"L33\"\nL31:         }\nL32:       ],\nL33:       \"caveat\": \"These quantitative readouts are summary values and mechanistic effects were not uniformly identical across all models.\"\nL34:     },\nL35:     {\nL36:       \"claim_id\": \"C03\",\nL37:       \"claim\": \"Type I interferon signaling is a required mechanism in this sensitization process in the reported experiments.\",\nL38:       \"strength\": \"strong\",\nL39:       \"evidence\": [\nL40:         {\nL41:           \"quote\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\nL42:           \"line_ref\": \"L39\"\nL43:         },\nL44:         {\nL45:           \"quote\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\nL46:           \"line_ref\": \"L42\"\nL47:         }\nL48:       ],\nL49:       \"caveat\": \"Causality is best supported in mechanistic mouse experiments and has not been proven as the dominant driver clinically.\"\nL50:     },\nL51:     {\nL52:       \"claim_id\": \"C04\",\nL53:       \"claim\": \"Retrospective human data suggest a survival advantage for vaccinated patients receiving immune checkpoint blockade.\",\nL54:       \"strength\": \"tentative\",\nL55:       \"evidence\": [\nL56:         {\nL57:           \"quote\": \"Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment\",\nL58:           \"line_ref\": \"L30\"\nL59:         },\nL60:         {\nL61:           \"quote\": \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\nL62:           \"line_ref\": \"L49\"\nL63:         }\nL64:       ],\nL65:       \"caveat\": \"Causal interpretation is limited by non-randomized design, variable vaccination timing, and heterogeneity in tumor types and treatment history.\"\nL66:     }\nL67:   ]\nL68: }",
            "callId": "call_toY3jxlv51cjRARsiVnII291"
          }
        ],
        "usage": {
          "promptTokens": 18026,
          "cachedTokens": 17024,
          "responseTokens": 32,
          "thinkingTokens": 0,
          "totalTokens": 18058
        },
        "costUsd": 0.0007401
      },
      {
        "step": 20,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/study_overview.json",
              "offset": 0,
              "limit": 500
            },
            "output": "L1: {\nL2:   \"paper\": {\nL3:     \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\nL4:     \"doi\": \"10.1038/s41586-025-09006-8\",\nL5:     \"publication_year\": 2025,\nL6:     \"domain\": \"oncology-immunology\",\nL7:     \"study_type\": \"preclinical+retrospective\"\nL8:   },\nL9:   \"core_question\": \"Can intratumoral mRNA vaccination sensitize tumors to immune checkpoint blockade by improving antigen presentation and immune activation?\",\nL10:   \"datasets_or_cohorts\": [\nL11:     {\nL12:       \"id\": \"mouse-efficacy-combination\",\nL13:       \"label\": \"Mouse efficacy cohort\",\nL14:       \"sample_size_or_observations\": \"78 tumor-bearing mice\",\nL15:       \"description\": \"Preclinical arm across multiple murine tumor models combining intratumoral mRNA vaccine with anti-PD-L1, pooled across repeat experiments.\"\nL16:     },\nL17:     {\nL18:       \"id\": \"mouse-control-cohort\",\nL19:       \"label\": \"Mouse control cohort\",\nL20:       \"sample_size_or_observations\": \"84 tumor-bearing mice\",\nL21:       \"description\": \"Matched control setting including vaccine-only, ICI-only, and vehicle groups across the murine experiments.\"\nL22:     },\nL23:     {\nL24:       \"id\": \"human-retrospective-cohort\",\nL25:       \"label\": \"Retrospective metastatic cohort\",\nL26:       \"sample_size_or_observations\": \"130 patients\",\nL27:       \"description\": \"Retrospective cohort of metastatic patients receiving ICI treatment, stratified by prior SARS-CoV-2 mRNA vaccination status.\"\nL28:     },\nL29:     {\nL30:       \"id\": \"human-vaccinated-subgroup\",\nL31:       \"label\": \"Vaccinated subgroup\",\nL32:       \"sample_size_or_observations\": \"43 patients\",\nL33:       \"description\": \"Subgroup of the retrospective cohort with prior SARS-CoV-2 mRNA vaccination.\"\nL34:     },\nL35:     {\nL36:       \"id\": \"human-unvaccinated-subgroup\",\nL37:       \"label\": \"Unvaccinated subgroup\",\nL38:       \"sample_size_or_observations\": \"87 patients\",\nL39:       \"description\": \"Subgroup of the retrospective cohort without prior SARS-CoV-2 mRNA vaccination.\"\nL40:     }\nL41:   ],\nL42:   \"major_limitations\": [\nL43:     \"The human analysis is retrospective and non-randomized, so residual confounding is likely.\",\nL44:     \"Vaccination timing relative to ICI initiation varied across patients.\",\nL45:     \"Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\",\nL46:     \"Mouse model effects may not map one-to-one to all human tumors.\",\nL47:     \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all settings.\"\nL48:   ]\nL49: }",
            "callId": "call_vwFHMEjaipiLaP8uUaXGQBIi"
          }
        ],
        "usage": {
          "promptTokens": 18899,
          "cachedTokens": 17920,
          "responseTokens": 34,
          "thinkingTokens": 1177,
          "totalTokens": 20110
        },
        "costUsd": 0.0031147499999999995
      },
      {
        "step": 21,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/public_summary.json",
              "offset": 0,
              "limit": 1000
            },
            "output": "L1: {\nL2:   \"headline\": \"mRNA vaccine injections into tumors may make immune checkpoint therapy work better in some cancers\",\nL3:   \"plain_language_summary\": \"This study explored whether delivering SARS-CoV-2 mRNA-based vaccines directly into tumors could improve responses to anti-PD-L1. In mouse studies, the combination was linked to stronger antitumor signals such as broader antigen display and higher immune-cell presence. In a retrospective cohort of 130 metastatic patients (43 vaccinated and 87 unvaccinated), vaccinated patients had a reported survival association with ICI treatment (p=0.01). However, results are preli\nL4: \",\nL5:   \"what_is_new\": [\nL6:     \"Intratumoral mRNA vaccination may broaden tumor peptide presentation and increase immune-cell infiltration.\",\nL7:     \"The work links a larger tumor immunopeptidome and MHC-I repertoire with a potential benefit from adding anti-PD-L1.\",\nL8:     \"Type I interferon signaling appears necessary for full sensitization in mechanistic experiments, with anti-IFNAR1 blocking the effect.\"\nL9:   ],\nL10:   \"why_caution_is_needed\": [\nL11:     \"The human arm is retrospective and non-randomized, so causal claims are limited.\",\nL12:     \"Vaccination timing relative to ICI initiation varied across patients and could bias outcome comparisons.\",\nL13:     \"Not all mechanistic effects were universal across model systems, and mouse findings may not fully translate to humans.\",\nL14:     \"Residual confounding and tumor heterogeneity may explain part of the observed survival association.\",\nL15:     \"The study does not yet provide randomized clinical trial-level evidence for changing treatment protocols.\"\nL16:   ],\nL17:   \"glossary\": [\nL18:     {\nL19:       \"term\": \"mRNA vaccine\",\nL20:       \"definition\": \"A vaccine using messenger RNA to instruct cells to produce a protein; here delivered into the tumor to stimulate immunity.\"\nL21:     },\nL22:     {\nL23:       \"term\": \"PD-L1\",\nL24:       \"definition\": \"A protein that can suppress immune attack on tumors; anti-PD-L1 antibodies block this suppressive signal.\"\nL25:     },\nL26:     {\nL27:       \"term\": \"MHC-I\",\nL28:       \"definition\": \"A molecule on cells that presents protein fragments to CD8 T cells, helping immune recognition of targets.\"\nL29:     },\nL30:     {\nL31:       \"term\": \"Interferon\",\nL32:       \"definition\": \"A family of immune signaling molecules that amplify antiviral and anti-tumor responses, including antigen presentation.\"\nL33:     },\nL34:     {\nL35:       \"term\": \"Retrospective study\",\nL36:       \"definition\": \"A study that analyzes existing records rather than assigning treatments prospectively in a new trial.\"\nL37:     }\nL38:   ],\nL39:   \"open_questions\": [\nL40:     \"Which patients and cancer types benefit most from intratumoral mRNA priming strategies?\",\nL41:     \"Can prospective randomized trials replicate the human survival signal seen in vaccinated patients?\",\nL42:     \"What is the safest and most effective schedule for combining intratumoral mRNA vaccination with ICI?\",\nL43:     \"Can the observed benefits be maintained while minimizing inflammatory or autoimmune side effects?\"\nL44:   ]\nL45: }",
            "callId": "call_MRv9noHqJaoA43YrbuWBB5Y9"
          }
        ],
        "usage": {
          "promptTokens": 19636,
          "cachedTokens": 18816,
          "responseTokens": 33,
          "thinkingTokens": 603,
          "totalTokens": 20272
        },
        "costUsd": 0.0019474
      },
      {
        "step": 22,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/claim_audit.json",
              "offset": 0,
              "limit": 1000
            },
            "output": "L1: {\nL2:   \"claims\": [\nL3:     {\nL4:       \"claim_id\": \"C01\",\nL5:       \"claim\": \"Intratumoral mRNA vaccination can sensitize tumors to anti-PD-L1 checkpoint blockade and improve control when combined.\",\nL6:       \"strength\": \"moderate\",\nL7:       \"evidence\": [\nL8:         {\nL9:           \"quote\": \"Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\",\nL10:           \"line_ref\": \"L46\"\nL11:         },\nL12:         {\nL13:           \"quote\": \"Preclinical arm: multiple murine tumor models with intratumoral mRNA vaccine and anti-PD-L1 combinations.\",\nL14:           \"line_ref\": \"L14\"\nL15:         }\nL16:       ],\nL17:       \"caveat\": \"The human association is observational, and preclinical efficacy may not generalize to all human tumor settings.\"\nL18:     },\nL19:     {\nL20:       \"claim_id\": \"C02\",\nL21:       \"claim\": \"mRNA vaccination is associated with a broader antigenic landscape and greater immune-cell presence in tumors.\",\nL22:       \"strength\": \"strong\",\nL23:       \"evidence\": [\nL24:         {\nL25:           \"quote\": \"Broader antigen display after intratumoral mRNA vaccination\",\nL26:           \"line_ref\": \"L28\"\nL27:         },\nL28:         {\nL29:           \"quote\": \"Increased immune infiltration with combination therapy\",\nL30:           \"line_ref\": \"L33\"\nL31:         }\nL32:       ],\nL33:       \"caveat\": \"These quantitative readouts are summary values and mechanistic effects were not uniformly identical across all models.\"\nL34:     },\nL35:     {\nL36:       \"claim_id\": \"C03\",\nL37:       \"claim\": \"Type I interferon signaling is a required mechanism in this sensitization process in the reported experiments.\",\nL38:       \"strength\": \"strong\",\nL39:       \"evidence\": [\nL40:         {\nL41:           \"quote\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\nL42:           \"line_ref\": \"L39\"\nL43:         },\nL44:         {\nL45:           \"quote\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\nL46:           \"line_ref\": \"L42\"\nL47:         }\nL48:       ],\nL49:       \"caveat\": \"Causality is best supported in mechanistic mouse experiments and has not been proven as the dominant driver clinically.\"\nL50:     },\nL51:     {\nL52:       \"claim_id\": \"C04\",\nL53:       \"claim\": \"Retrospective human data suggest a survival advantage for vaccinated patients receiving immune checkpoint blockade.\",\nL54:       \"strength\": \"tentative\",\nL55:       \"evidence\": [\nL56:         {\nL57:           \"quote\": \"Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment\",\nL58:           \"line_ref\": \"L30\"\nL59:         },\nL60:         {\nL61:           \"quote\": \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\nL62:           \"line_ref\": \"L49\"\nL63:         }\nL64:       ],\nL65:       \"caveat\": \"Causal interpretation is limited by non-randomized design, variable vaccination timing, and heterogeneity in tumor types and treatment history.\"\nL66:     }\nL67:   ]\nL68: }",
            "callId": "call_zMn73Lf9MRFy056fvWiPO2Ln"
          }
        ],
        "usage": {
          "promptTokens": 20418,
          "cachedTokens": 19456,
          "responseTokens": 35,
          "thinkingTokens": 150,
          "totalTokens": 20603
        },
        "costUsd": 0.0010969
      },
      {
        "step": 23,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/study_overview.json",
              "offset": 0,
              "limit": 1000
            },
            "output": "L1: {\nL2:   \"paper\": {\nL3:     \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\nL4:     \"doi\": \"10.1038/s41586-025-09006-8\",\nL5:     \"publication_year\": 2025,\nL6:     \"domain\": \"oncology-immunology\",\nL7:     \"study_type\": \"preclinical+retrospective\"\nL8:   },\nL9:   \"core_question\": \"Can intratumoral mRNA vaccination sensitize tumors to immune checkpoint blockade by improving antigen presentation and immune activation?\",\nL10:   \"datasets_or_cohorts\": [\nL11:     {\nL12:       \"id\": \"mouse-efficacy-combination\",\nL13:       \"label\": \"Mouse efficacy cohort\",\nL14:       \"sample_size_or_observations\": \"78 tumor-bearing mice\",\nL15:       \"description\": \"Preclinical arm across multiple murine tumor models combining intratumoral mRNA vaccine with anti-PD-L1, pooled across repeat experiments.\"\nL16:     },\nL17:     {\nL18:       \"id\": \"mouse-control-cohort\",\nL19:       \"label\": \"Mouse control cohort\",\nL20:       \"sample_size_or_observations\": \"84 tumor-bearing mice\",\nL21:       \"description\": \"Matched control setting including vaccine-only, ICI-only, and vehicle groups across the murine experiments.\"\nL22:     },\nL23:     {\nL24:       \"id\": \"human-retrospective-cohort\",\nL25:       \"label\": \"Retrospective metastatic cohort\",\nL26:       \"sample_size_or_observations\": \"130 patients\",\nL27:       \"description\": \"Retrospective cohort of metastatic patients receiving ICI treatment, stratified by prior SARS-CoV-2 mRNA vaccination status.\"\nL28:     },\nL29:     {\nL30:       \"id\": \"human-vaccinated-subgroup\",\nL31:       \"label\": \"Vaccinated subgroup\",\nL32:       \"sample_size_or_observations\": \"43 patients\",\nL33:       \"description\": \"Subgroup of the retrospective cohort with prior SARS-CoV-2 mRNA vaccination.\"\nL34:     },\nL35:     {\nL36:       \"id\": \"human-unvaccinated-subgroup\",\nL37:       \"label\": \"Unvaccinated subgroup\",\nL38:       \"sample_size_or_observations\": \"87 patients\",\nL39:       \"description\": \"Subgroup of the retrospective cohort without prior SARS-CoV-2 mRNA vaccination.\"\nL40:     }\nL41:   ],\nL42:   \"major_limitations\": [\nL43:     \"The human analysis is retrospective and non-randomized, so residual confounding is likely.\",\nL44:     \"Vaccination timing relative to ICI initiation varied across patients.\",\nL45:     \"Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\",\nL46:     \"Mouse model effects may not map one-to-one to all human tumors.\",\nL47:     \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all settings.\"\nL48:   ]\nL49: }",
            "callId": "call_XWSMrQVUN5yQhazZMVsM4mmX"
          }
        ],
        "usage": {
          "promptTokens": 21292,
          "cachedTokens": 20224,
          "responseTokens": 35,
          "thinkingTokens": 216,
          "totalTokens": 21543
        },
        "costUsd": 0.0012745999999999999
      },
      {
        "step": 24,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/public_summary.json",
              "offset": 0,
              "limit": 1200
            },
            "output": "L1: {\nL2:   \"headline\": \"mRNA vaccine injections into tumors may make immune checkpoint therapy work better in some cancers\",\nL3:   \"plain_language_summary\": \"This study explored whether delivering SARS-CoV-2 mRNA-based vaccines directly into tumors could improve responses to anti-PD-L1. In mouse studies, the combination was linked to stronger antitumor signals such as broader antigen display and higher immune-cell presence. In a retrospective cohort of 130 metastatic patients (43 vaccinated and 87 unvaccinated), vaccinated patients had a reported survival association with ICI treatment (p=0.01). However, results are preli\nL4: \",\nL5:   \"what_is_new\": [\nL6:     \"Intratumoral mRNA vaccination may broaden tumor peptide presentation and increase immune-cell infiltration.\",\nL7:     \"The work links a larger tumor immunopeptidome and MHC-I repertoire with a potential benefit from adding anti-PD-L1.\",\nL8:     \"Type I interferon signaling appears necessary for full sensitization in mechanistic experiments, with anti-IFNAR1 blocking the effect.\"\nL9:   ],\nL10:   \"why_caution_is_needed\": [\nL11:     \"The human arm is retrospective and non-randomized, so causal claims are limited.\",\nL12:     \"Vaccination timing relative to ICI initiation varied across patients and could bias outcome comparisons.\",\nL13:     \"Not all mechanistic effects were universal across model systems, and mouse findings may not fully translate to humans.\",\nL14:     \"Residual confounding and tumor heterogeneity may explain part of the observed survival association.\",\nL15:     \"The study does not yet provide randomized clinical trial-level evidence for changing treatment protocols.\"\nL16:   ],\nL17:   \"glossary\": [\nL18:     {\nL19:       \"term\": \"mRNA vaccine\",\nL20:       \"definition\": \"A vaccine using messenger RNA to instruct cells to produce a protein; here delivered into the tumor to stimulate immunity.\"\nL21:     },\nL22:     {\nL23:       \"term\": \"PD-L1\",\nL24:       \"definition\": \"A protein that can suppress immune attack on tumors; anti-PD-L1 antibodies block this suppressive signal.\"\nL25:     },\nL26:     {\nL27:       \"term\": \"MHC-I\",\nL28:       \"definition\": \"A molecule on cells that presents protein fragments to CD8 T cells, helping immune recognition of targets.\"\nL29:     },\nL30:     {\nL31:       \"term\": \"Interferon\",\nL32:       \"definition\": \"A family of immune signaling molecules that amplify antiviral and anti-tumor responses, including antigen presentation.\"\nL33:     },\nL34:     {\nL35:       \"term\": \"Retrospective study\",\nL36:       \"definition\": \"A study that analyzes existing records rather than assigning treatments prospectively in a new trial.\"\nL37:     }\nL38:   ],\nL39:   \"open_questions\": [\nL40:     \"Which patients and cancer types benefit most from intratumoral mRNA priming strategies?\",\nL41:     \"Can prospective randomized trials replicate the human survival signal seen in vaccinated patients?\",\nL42:     \"What is the safest and most effective schedule for combining intratumoral mRNA vaccination with ICI?\",\nL43:     \"Can the observed benefits be maintained while minimizing inflammatory or autoimmune side effects?\"\nL44:   ]\nL45: }",
            "callId": "call_KfQDOMqeHOW1MNgp9TLkQl9o"
          }
        ],
        "usage": {
          "promptTokens": 22030,
          "cachedTokens": 21120,
          "responseTokens": 33,
          "thinkingTokens": 835,
          "totalTokens": 22898
        },
        "costUsd": 0.0024915
      },
      {
        "step": 25,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/study_overview.json",
              "offset": 0,
              "limit": 500
            },
            "output": "L1: {\nL2:   \"paper\": {\nL3:     \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\nL4:     \"doi\": \"10.1038/s41586-025-09006-8\",\nL5:     \"publication_year\": 2025,\nL6:     \"domain\": \"oncology-immunology\",\nL7:     \"study_type\": \"preclinical+retrospective\"\nL8:   },\nL9:   \"core_question\": \"Can intratumoral mRNA vaccination sensitize tumors to immune checkpoint blockade by improving antigen presentation and immune activation?\",\nL10:   \"datasets_or_cohorts\": [\nL11:     {\nL12:       \"id\": \"mouse-efficacy-combination\",\nL13:       \"label\": \"Mouse efficacy cohort\",\nL14:       \"sample_size_or_observations\": \"78 tumor-bearing mice\",\nL15:       \"description\": \"Preclinical arm across multiple murine tumor models combining intratumoral mRNA vaccine with anti-PD-L1, pooled across repeat experiments.\"\nL16:     },\nL17:     {\nL18:       \"id\": \"mouse-control-cohort\",\nL19:       \"label\": \"Mouse control cohort\",\nL20:       \"sample_size_or_observations\": \"84 tumor-bearing mice\",\nL21:       \"description\": \"Matched control setting including vaccine-only, ICI-only, and vehicle groups across the murine experiments.\"\nL22:     },\nL23:     {\nL24:       \"id\": \"human-retrospective-cohort\",\nL25:       \"label\": \"Retrospective metastatic cohort\",\nL26:       \"sample_size_or_observations\": \"130 patients\",\nL27:       \"description\": \"Retrospective cohort of metastatic patients receiving ICI treatment, stratified by prior SARS-CoV-2 mRNA vaccination status.\"\nL28:     },\nL29:     {\nL30:       \"id\": \"human-vaccinated-subgroup\",\nL31:       \"label\": \"Vaccinated subgroup\",\nL32:       \"sample_size_or_observations\": \"43 patients\",\nL33:       \"description\": \"Subgroup of the retrospective cohort with prior SARS-CoV-2 mRNA vaccination.\"\nL34:     },\nL35:     {\nL36:       \"id\": \"human-unvaccinated-subgroup\",\nL37:       \"label\": \"Unvaccinated subgroup\",\nL38:       \"sample_size_or_observations\": \"87 patients\",\nL39:       \"description\": \"Subgroup of the retrospective cohort without prior SARS-CoV-2 mRNA vaccination.\"\nL40:     }\nL41:   ],\nL42:   \"major_limitations\": [\nL43:     \"The human analysis is retrospective and non-randomized, so residual confounding is likely.\",\nL44:     \"Vaccination timing relative to ICI initiation varied across patients.\",\nL45:     \"Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\",\nL46:     \"Mouse model effects may not map one-to-one to all human tumors.\",\nL47:     \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all settings.\"\nL48:   ]\nL49: }",
            "callId": "call_yWKwa6A051neVz3LQnY89aRi"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/quantitative_findings.json",
              "offset": 0,
              "limit": 700
            },
            "output": "L1: {\nL2:   \"findings\": [\nL3:     {\nL4:       \"id\": \"Q01\",\nL5:       \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\nL6:       \"value\": \"62.3%\",\nL7:       \"comparator_or_baseline\": \"37.3%\",\nL8:       \"interpretation\": \"Broader antigen display after intratumoral mRNA vaccination\",\nL9:       \"evidence_line_refs\": [\"L28\"]\nL10:     },\nL11:     {\nL12:       \"id\": \"Q02\",\nL13:       \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\nL14:       \"value\": \"40.6%\",\nL15:       \"comparator_or_baseline\": \"20.6%\",\nL16:       \"interpretation\": \"Strong expansion of MHC-I-presented landscape\",\nL17:       \"evidence_line_refs\": [\"L29\"]\nL18:     },\nL19:     {\nL20:       \"id\": \"Q03\",\nL21:       \"metric\": \"Retrospective human survival comparison p-value\",\nL22:       \"value\": \"p=0.01\",\nL23:       \"comparator_or_baseline\": \"N/A\",\nL24:       \"interpretation\": \"Vaccinated subgroup had improved survival under ICI treatment\",\nL25:       \"evidence_line_refs\": [\"L30\"]\nL26:     },\nL27:     {\nL28:       \"id\": \"Q04\",\nL29:       \"metric\": \"Type I interferon response score (normalized units)\",\nL30:       \"value\": \"3.1\",\nL31:       \"comparator_or_baseline\": \"1.0\",\nL32:       \"interpretation\": \"Marked induction after mRNA vaccination in tumors\",\nL33:       \"evidence_line_refs\": [\"L31\"]\nL34:     },\nL35:     {\nL36:       \"id\": \"Q05\",\nL37:       \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\nL38:       \"value\": \"2.4x\",\nL39:       \"comparator_or_baseline\": \"1.0x\",\nL40:       \"interpretation\": \"Checkpoint axis became more targetable\",\nL41:       \"evidence_line_refs\": [\"L32\"]\nL42:     },\nL43:     {\nL44:       \"id\": \"Q06\",\nL45:       \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\nL46:       \"value\": \"1.8x\",\nL47:       \"comparator_or_baseline\": \"1.0x\",\nL48:       \"interpretation\": \"Increased immune infiltration with combination therapy\",\nL49:       \"evidence_line_refs\": [\"L33\"]\nL50:     }\nL51:   ],\nL52:   \"controls_or_null_results\": [\nL53:     {\nL54:       \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\nL55:       \"evidence_line_ref\": \"L36\"\nL56:     },\nL57:     {\nL58:       \"statement\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\nL59:       \"evidence_line_ref\": \"L37\"\nL60:     },\nL61:     {\nL62:       \"statement\": \"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\nL63:       \"evidence_line_ref\": \"L38\"\nL64:     },\nL65:     {\nL66:       \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\nL67:       \"evidence_line_ref\": \"L39\"\nL68:     }\nL69:   ]\nL70: }",
            "callId": "call_GAzrOfjyNYyvyutLpshouHks"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/claim_audit.json",
              "offset": 0,
              "limit": 900
            },
            "output": "L1: {\nL2:   \"claims\": [\nL3:     {\nL4:       \"claim_id\": \"C01\",\nL5:       \"claim\": \"Intratumoral mRNA vaccination can sensitize tumors to anti-PD-L1 checkpoint blockade and improve control when combined.\",\nL6:       \"strength\": \"moderate\",\nL7:       \"evidence\": [\nL8:         {\nL9:           \"quote\": \"Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\",\nL10:           \"line_ref\": \"L46\"\nL11:         },\nL12:         {\nL13:           \"quote\": \"Preclinical arm: multiple murine tumor models with intratumoral mRNA vaccine and anti-PD-L1 combinations.\",\nL14:           \"line_ref\": \"L14\"\nL15:         }\nL16:       ],\nL17:       \"caveat\": \"The human association is observational, and preclinical efficacy may not generalize to all human tumor settings.\"\nL18:     },\nL19:     {\nL20:       \"claim_id\": \"C02\",\nL21:       \"claim\": \"mRNA vaccination is associated with a broader antigenic landscape and greater immune-cell presence in tumors.\",\nL22:       \"strength\": \"strong\",\nL23:       \"evidence\": [\nL24:         {\nL25:           \"quote\": \"Broader antigen display after intratumoral mRNA vaccination\",\nL26:           \"line_ref\": \"L28\"\nL27:         },\nL28:         {\nL29:           \"quote\": \"Increased immune infiltration with combination therapy\",\nL30:           \"line_ref\": \"L33\"\nL31:         }\nL32:       ],\nL33:       \"caveat\": \"These quantitative readouts are summary values and mechanistic effects were not uniformly identical across all models.\"\nL34:     },\nL35:     {\nL36:       \"claim_id\": \"C03\",\nL37:       \"claim\": \"Type I interferon signaling is a required mechanism in this sensitization process in the reported experiments.\",\nL38:       \"strength\": \"strong\",\nL39:       \"evidence\": [\nL40:         {\nL41:           \"quote\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\nL42:           \"line_ref\": \"L39\"\nL43:         },\nL44:         {\nL45:           \"quote\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\nL46:           \"line_ref\": \"L42\"\nL47:         }\nL48:       ],\nL49:       \"caveat\": \"Causality is best supported in mechanistic mouse experiments and has not been proven as the dominant driver clinically.\"\nL50:     },\nL51:     {\nL52:       \"claim_id\": \"C04\",\nL53:       \"claim\": \"Retrospective human data suggest a survival advantage for vaccinated patients receiving immune checkpoint blockade.\",\nL54:       \"strength\": \"tentative\",\nL55:       \"evidence\": [\nL56:         {\nL57:           \"quote\": \"Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment\",\nL58:           \"line_ref\": \"L30\"\nL59:         },\nL60:         {\nL61:           \"quote\": \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\nL62:           \"line_ref\": \"L49\"\nL63:         }\nL64:       ],\nL65:       \"caveat\": \"Causal interpretation is limited by non-randomized design, variable vaccination timing, and heterogeneity in tumor types and treatment history.\"\nL66:     }\nL67:   ]\nL68: }",
            "callId": "call_d0D9Ytn2GiTdlXa6vDbAfeBk"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/public_summary.json",
              "offset": 0,
              "limit": 900
            },
            "output": "L1: {\nL2:   \"headline\": \"mRNA vaccine injections into tumors may make immune checkpoint therapy work better in some cancers\",\nL3:   \"plain_language_summary\": \"This study explored whether delivering SARS-CoV-2 mRNA-based vaccines directly into tumors could improve responses to anti-PD-L1. In mouse studies, the combination was linked to stronger antitumor signals such as broader antigen display and higher immune-cell presence. In a retrospective cohort of 130 metastatic patients (43 vaccinated and 87 unvaccinated), vaccinated patients had a reported survival association with ICI treatment (p=0.01). However, results are preli\nL4: \",\nL5:   \"what_is_new\": [\nL6:     \"Intratumoral mRNA vaccination may broaden tumor peptide presentation and increase immune-cell infiltration.\",\nL7:     \"The work links a larger tumor immunopeptidome and MHC-I repertoire with a potential benefit from adding anti-PD-L1.\",\nL8:     \"Type I interferon signaling appears necessary for full sensitization in mechanistic experiments, with anti-IFNAR1 blocking the effect.\"\nL9:   ],\nL10:   \"why_caution_is_needed\": [\nL11:     \"The human arm is retrospective and non-randomized, so causal claims are limited.\",\nL12:     \"Vaccination timing relative to ICI initiation varied across patients and could bias outcome comparisons.\",\nL13:     \"Not all mechanistic effects were universal across model systems, and mouse findings may not fully translate to humans.\",\nL14:     \"Residual confounding and tumor heterogeneity may explain part of the observed survival association.\",\nL15:     \"The study does not yet provide randomized clinical trial-level evidence for changing treatment protocols.\"\nL16:   ],\nL17:   \"glossary\": [\nL18:     {\nL19:       \"term\": \"mRNA vaccine\",\nL20:       \"definition\": \"A vaccine using messenger RNA to instruct cells to produce a protein; here delivered into the tumor to stimulate immunity.\"\nL21:     },\nL22:     {\nL23:       \"term\": \"PD-L1\",\nL24:       \"definition\": \"A protein that can suppress immune attack on tumors; anti-PD-L1 antibodies block this suppressive signal.\"\nL25:     },\nL26:     {\nL27:       \"term\": \"MHC-I\",\nL28:       \"definition\": \"A molecule on cells that presents protein fragments to CD8 T cells, helping immune recognition of targets.\"\nL29:     },\nL30:     {\nL31:       \"term\": \"Interferon\",\nL32:       \"definition\": \"A family of immune signaling molecules that amplify antiviral and anti-tumor responses, including antigen presentation.\"\nL33:     },\nL34:     {\nL35:       \"term\": \"Retrospective study\",\nL36:       \"definition\": \"A study that analyzes existing records rather than assigning treatments prospectively in a new trial.\"\nL37:     }\nL38:   ],\nL39:   \"open_questions\": [\nL40:     \"Which patients and cancer types benefit most from intratumoral mRNA priming strategies?\",\nL41:     \"Can prospective randomized trials replicate the human survival signal seen in vaccinated patients?\",\nL42:     \"What is the safest and most effective schedule for combining intratumoral mRNA vaccination with ICI?\",\nL43:     \"Can the observed benefits be maintained while minimizing inflammatory or autoimmune side effects?\"\nL44:   ]\nL45: }",
            "callId": "call_6ONfnUUIPfn3JkJds1UODR70"
          }
        ],
        "usage": {
          "promptTokens": 22812,
          "cachedTokens": 21888,
          "responseTokens": 133,
          "thinkingTokens": 805,
          "totalTokens": 23750
        },
        "costUsd": 0.0026542
      },
      {
        "step": 26,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/study_overview.json",
              "offset": 0,
              "limit": 300
            },
            "output": "L1: {\nL2:   \"paper\": {\nL3:     \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\nL4:     \"doi\": \"10.1038/s41586-025-09006-8\",\nL5:     \"publication_year\": 2025,\nL6:     \"domain\": \"oncology-immunology\",\nL7:     \"study_type\": \"preclinical+retrospective\"\nL8:   },\nL9:   \"core_question\": \"Can intratumoral mRNA vaccination sensitize tumors to immune checkpoint blockade by improving antigen presentation and immune activation?\",\nL10:   \"datasets_or_cohorts\": [\nL11:     {\nL12:       \"id\": \"mouse-efficacy-combination\",\nL13:       \"label\": \"Mouse efficacy cohort\",\nL14:       \"sample_size_or_observations\": \"78 tumor-bearing mice\",\nL15:       \"description\": \"Preclinical arm across multiple murine tumor models combining intratumoral mRNA vaccine with anti-PD-L1, pooled across repeat experiments.\"\nL16:     },\nL17:     {\nL18:       \"id\": \"mouse-control-cohort\",\nL19:       \"label\": \"Mouse control cohort\",\nL20:       \"sample_size_or_observations\": \"84 tumor-bearing mice\",\nL21:       \"description\": \"Matched control setting including vaccine-only, ICI-only, and vehicle groups across the murine experiments.\"\nL22:     },\nL23:     {\nL24:       \"id\": \"human-retrospective-cohort\",\nL25:       \"label\": \"Retrospective metastatic cohort\",\nL26:       \"sample_size_or_observations\": \"130 patients\",\nL27:       \"description\": \"Retrospective cohort of metastatic patients receiving ICI treatment, stratified by prior SARS-CoV-2 mRNA vaccination status.\"\nL28:     },\nL29:     {\nL30:       \"id\": \"human-vaccinated-subgroup\",\nL31:       \"label\": \"Vaccinated subgroup\",\nL32:       \"sample_size_or_observations\": \"43 patients\",\nL33:       \"description\": \"Subgroup of the retrospective cohort with prior SARS-CoV-2 mRNA vaccination.\"\nL34:     },\nL35:     {\nL36:       \"id\": \"human-unvaccinated-subgroup\",\nL37:       \"label\": \"Unvaccinated subgroup\",\nL38:       \"sample_size_or_observations\": \"87 patients\",\nL39:       \"description\": \"Subgroup of the retrospective cohort without prior SARS-CoV-2 mRNA vaccination.\"\nL40:     }\nL41:   ],\nL42:   \"major_limitations\": [\nL43:     \"The human analysis is retrospective and non-randomized, so residual confounding is likely.\",\nL44:     \"Vaccination timing relative to ICI initiation varied across patients.\",\nL45:     \"Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\",\nL46:     \"Mouse model effects may not map one-to-one to all human tumors.\",\nL47:     \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all settings.\"\nL48:   ]\nL49: }",
            "callId": "call_QpsvVrGvKs9dTdoJaCHy9ANO"
          }
        ],
        "usage": {
          "promptTokens": 26087,
          "cachedTokens": 22656,
          "responseTokens": 34,
          "thinkingTokens": 763,
          "totalTokens": 26884
        },
        "costUsd": 0.00301815
      },
      {
        "step": 27,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "text": "âœ… **Completion checklist**\n- [x] `output/study_overview.json` written\n- [x] `output/quantitative_findings.json` written\n- [x] `output/claim_audit.json` written\n- [x] `output/public_summary.json` written",
        "toolCalls": [],
        "usage": {
          "promptTokens": 26824,
          "cachedTokens": 25984,
          "responseTokens": 65,
          "thinkingTokens": 1950,
          "totalTokens": 28839
        },
        "costUsd": 0.0048896
      }
    ],
    "totalCostUsd": 0.05975624999999999
  }
}
